1
|
Tjoumakaris SI, Hanel R, Mocco J, Ali-Aziz Sultan M, Froehler M, Lieber BB, Coon A, Tateshima S, Altschul DJ, Narayanan S, El Naamani K, Taussky P, Hoh BL, Meyers P, Gounis MJ, Liebeskind DS, Volovici V, Toth G, Arthur A, Wakhloo AK. ARISE I Consensus Review on the Management of Intracranial Aneurysms. Stroke 2024; 55:1428-1437. [PMID: 38648283 DOI: 10.1161/strokeaha.123.046208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2023] [Accepted: 03/19/2024] [Indexed: 04/25/2024]
Abstract
BACKGROUND Intracranial aneurysms (IAs) remain a challenging neurological diagnosis associated with significant morbidity and mortality. There is a plethora of microsurgical and endovascular techniques for the treatment of both ruptured and unruptured aneurysms. There is no definitive consensus as to the best treatment option for this cerebrovascular pathology. The Aneurysm, Arteriovenous Malformation, and Chronic Subdural Hematoma Roundtable Discussion With Industry and Stroke Experts discussed best practices and the most promising approaches to improve the management of brain aneurysms. METHODS A group of experts from academia, industry, and federal regulators convened to discuss updated clinical trials, scientific research on preclinical system models, management options, screening and monitoring, and promising novel device technologies, aiming to improve the outcomes of patients with IA. RESULTS Aneurysm, Arteriovenous Malformation, and Chronic Subdural Hematoma Roundtable Discussion With Industry and Stroke Experts suggested the incorporation of artificial intelligence to capture sequential aneurysm growth, identify predictors of rupture, and predict the risk of rupture to guide treatment options. The consensus strongly recommended nationwide systemic data collection of unruptured IA radiographic images for the analysis and development of machine learning algorithms for rupture risk. The consensus supported centers of excellence for preclinical multicenter trials in areas such as genetics, cellular composition, and radiogenomics. Optical coherence tomography and magnetic resonance imaging contrast-enhanced 3T vessel wall imaging are promising technologies; however, more data are needed to define their role in IA management. Ruptured aneurysms are best managed at large volume centers, which should include comprehensive patient management with expertise in microsurgery, endovascular surgery, neurology, and neurocritical care. CONCLUSIONS Clinical and preclinical studies and scientific research on IA should engage high-volume centers and be conducted in multicenter collaborative efforts. The future of IA diagnosis and monitoring could be enhanced by the incorporation of artificial intelligence and national radiographic and biologic registries. A collaborative effort between academic centers, government regulators, and the device industry is paramount for the adequate management of IA and the advancement of the field.
Collapse
Affiliation(s)
- Stavropoula I Tjoumakaris
- Department of Neurosurgery, Thomas Jefferson University at Sidney Kimmel Medical College, Philadelphia, PA (S.I.T., K.E.N.)
| | - Ricardo Hanel
- Baptist Neurological Institute, Jacksonville, FL (R.H.)
| | - J Mocco
- Department of Neurosurgery, Mount Sinai University Hospital, New York, NY (J.M.)
| | - M Ali-Aziz Sultan
- Department of Neurosurgery, Harvard Medical School, Boston, MA (M.A.-A.S.)
| | - Michael Froehler
- Department of Neurology, Vanderbilt University, Nashville, TN (M.F.)
| | - Barry B Lieber
- Department of Neurology, Tufts School of Medicine, Boston, MA (B.B.L.)
| | - Alexander Coon
- Department of Neurosurgery, Carondelet Neurological Institute of St. Joseph's and St. Mary's Hospitals in Tucson, AZ (A.C.)
| | - Satoshi Tateshima
- Department of Radiology (S.T.), University of California, Los Angeles
| | - David J Altschul
- Department of Neurological Surgery, Einstein Montefiore Medical Center, Bronx, NY (D.J.A.)
| | - Sandra Narayanan
- Department of Neurology, Pacific Neuroscience Institute, Santa Monica, CA (S.N.)
| | - Kareem El Naamani
- Department of Neurosurgery, Thomas Jefferson University at Sidney Kimmel Medical College, Philadelphia, PA (S.I.T., K.E.N.)
| | - Phil Taussky
- Department of Neurosurgery, Beth Israel Deaconess Medical Center, Boston, MA (P.T.)
| | - Brian L Hoh
- Department of Neurosurgery, University of Florida, Gainesville (B.L.H.)
| | - Philip Meyers
- Department of Radiology, Saint Luke's Clinic, Boise, ID (P.M.)
| | - Matthew J Gounis
- Department of Radiology, University of Massachusetts, Worcester (M.J.G.)
| | | | - Victor Volovici
- Department of Neurosurgery, Erasmus MC Stroke Center, Erasmus MC University Medical Center, Rotterdam, the Netherlands (V.V.)
| | - Gabor Toth
- Department of Neurosurgery, Cleveland Clinic, OH (G.T.)
| | - Adam Arthur
- Department of Neurosurgery, Semmes Murphey Clinic, Memphis, TN (A.A.)
| | - Ajay K Wakhloo
- Department of Radiology, Tufts University School of Medicine, Boston, MA (A.K.W.)
| |
Collapse
|
2
|
Sarraj A, Hassan AE, Abraham MG, Ortega-Gutierrez S, Kasner SE, Hussain MS, Chen M, Churilov L, Johns H, Sitton CW, Yogendrakumar V, Ng FC, Pujara DK, Blackburn S, Sundararajan S, Hu YC, Herial NA, Arenillas JF, Tsai JP, Budzik RF, Hicks WJ, Kozak O, Yan B, Cordato DJ, Manning NW, Parsons MW, Cheung A, Hanel RA, Aghaebrahim AN, Wu TY, Portela PC, Gandhi CD, Al-Mufti F, Pérez de la Ossa N, Schaafsma JD, Blasco J, Sangha N, Warach S, Kleinig TJ, Shaker F, Al Shaibi F, Toth G, Abdulrazzak MA, Sharma G, Ray A, Sunshine J, Opaskar A, Duncan KR, Xiong W, Samaniego EA, Maali L, Lechtenberg CG, Renú A, Vora N, Nguyen T, Fifi JT, Tjoumakaris SI, Jabbour P, Tsivgoulis G, Pereira VM, Lansberg MG, DeGeorgia M, Sila CA, Bambakidis N, Hill MD, Davis SM, Wechsler L, Grotta JC, Ribo M, Albers GW, Campbell BC. Endovascular Thrombectomy for Large Ischemic Stroke Across Ischemic Injury and Penumbra Profiles. JAMA 2024; 331:750-763. [PMID: 38324414 PMCID: PMC10851143 DOI: 10.1001/jama.2024.0572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/28/2023] [Accepted: 01/16/2024] [Indexed: 02/09/2024]
Abstract
Importance Whether endovascular thrombectomy (EVT) efficacy for patients with acute ischemic stroke and large cores varies depending on the extent of ischemic injury is uncertain. Objective To describe the relationship between imaging estimates of irreversibly injured brain (core) and at-risk regions (mismatch) and clinical outcomes and EVT treatment effect. Design, Setting, and Participants An exploratory analysis of the SELECT2 trial, which randomized 352 adults (18-85 years) with acute ischemic stroke due to occlusion of the internal carotid or middle cerebral artery (M1 segment) and large ischemic core to EVT vs medical management (MM), across 31 global centers between October 2019 and September 2022. Intervention EVT vs MM. Main Outcomes and Measures Primary outcome was functional outcome-90-day mRS score (0, no symptoms, to 6, death) assessed by adjusted generalized OR (aGenOR; values >1 represent more favorable outcomes). Benefit of EVT vs MM was assessed across levels of ischemic injury defined by noncontrast CT using ASPECTS score and by the volume of brain with severely reduced blood flow on CT perfusion or restricted diffusion on MRI. Results Among 352 patients randomized, 336 were analyzed (median age, 67 years; 139 [41.4%] female); of these, 168 (50%) were randomized to EVT, and 2 additional crossover MM patients received EVT. In an ordinal analysis of mRS at 90 days, EVT improved functional outcomes compared with MM within ASPECTS categories of 3 (aGenOR, 1.71 [95% CI, 1.04-2.81]), 4 (aGenOR, 2.01 [95% CI, 1.19-3.40]), and 5 (aGenOR, 1.85 [95% CI, 1.22-2.79]). Across strata for CT perfusion/MRI ischemic core volumes, aGenOR for EVT vs MM was 1.63 (95% CI, 1.23-2.16) for volumes ≥70 mL, 1.41 (95% CI, 0.99-2.02) for ≥100 mL, and 1.47 (95% CI, 0.84-2.56) for ≥150 mL. In the EVT group, outcomes worsened as ASPECTS decreased (aGenOR, 0.91 [95% CI, 0.82-1.00] per 1-point decrease) and as CT perfusion/MRI ischemic core volume increased (aGenOR, 0.92 [95% CI, 0.89-0.95] per 10-mL increase). No heterogeneity of EVT treatment effect was observed with or without mismatch, although few patients without mismatch were enrolled. Conclusion and Relevance In this exploratory analysis of a randomized clinical trial of patients with extensive ischemic stroke, EVT improved clinical outcomes across a wide spectrum of infarct volumes, although enrollment of patients with minimal penumbra volume was low. In EVT-treated patients, clinical outcomes worsened as presenting ischemic injury estimates increased. Trial Registration ClinicalTrials.gov Identifier: NCT03876457.
Collapse
Affiliation(s)
- Amrou Sarraj
- University Hospital Cleveland Medical Center—Case Western Reserve University, Cleveland, Ohio
| | | | | | | | | | | | - Michael Chen
- Rush University Medical Center, Chicago, Illinois
| | - Leonid Churilov
- The Melbourne Brain Centre, Royal Melbourne Hospital and University of Melbourne, Melbourne, Victoria, Australia
| | - Hannah Johns
- The Melbourne Brain Centre, Royal Melbourne Hospital and University of Melbourne, Melbourne, Victoria, Australia
| | | | - Vignan Yogendrakumar
- The Melbourne Brain Centre, Royal Melbourne Hospital and University of Melbourne, Melbourne, Victoria, Australia
| | - Felix C. Ng
- The Melbourne Brain Centre, Royal Melbourne Hospital and University of Melbourne, Melbourne, Victoria, Australia
| | - Deep K. Pujara
- University Hospital Cleveland Medical Center—Case Western Reserve University, Cleveland, Ohio
| | | | - Sophia Sundararajan
- University Hospital Cleveland Medical Center—Case Western Reserve University, Cleveland, Ohio
| | - Yin C. Hu
- University Hospital Cleveland Medical Center—Case Western Reserve University, Cleveland, Ohio
| | - Nabeel A. Herial
- Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
| | - Juan F. Arenillas
- Hospital Clínico Universitario Valladolid—University of Valladolid, Valladolid, Spain
| | | | | | | | - Osman Kozak
- Abington Jefferson Health, Abington, Pennsylvania
| | - Bernard Yan
- The Melbourne Brain Centre, Royal Melbourne Hospital and University of Melbourne, Melbourne, Victoria, Australia
| | | | | | | | - Andrew Cheung
- Liverpool Hospital, Liverpool, New South Wales, Australia
| | | | | | - Teddy Y. Wu
- Christchurch Hospital, Christchurch, New Zealand
| | | | | | - Fawaz Al-Mufti
- Westchester Medical Center, New York Medical College, Valhalla
| | | | | | | | | | - Steven Warach
- Dell Medical School at The University of Texas at Austin–Ascension Texas, Austin
| | | | - Faris Shaker
- McGovern Medical School at UTHealth, Houston, Texas
| | - Faisal Al Shaibi
- University Hospital Cleveland Medical Center—Case Western Reserve University, Cleveland, Ohio
| | | | | | - Gagan Sharma
- The Melbourne Brain Centre, Royal Melbourne Hospital and University of Melbourne, Melbourne, Victoria, Australia
| | - Abhishek Ray
- University Hospital Cleveland Medical Center—Case Western Reserve University, Cleveland, Ohio
| | - Jeffrey Sunshine
- University Hospital Cleveland Medical Center—Case Western Reserve University, Cleveland, Ohio
| | - Amanda Opaskar
- University Hospital Cleveland Medical Center—Case Western Reserve University, Cleveland, Ohio
| | - Kelsey R. Duncan
- University Hospital Cleveland Medical Center—Case Western Reserve University, Cleveland, Ohio
| | - Wei Xiong
- University Hospital Cleveland Medical Center—Case Western Reserve University, Cleveland, Ohio
| | | | - Laith Maali
- University of Kansas Medical Center, Kansas City
| | | | - Arturo Renú
- Hospital Clínic de Barcelona, Barcelona, Spain
| | - Nirav Vora
- Riverside Methodist Hospital, OhioHealth, Columbus
| | | | | | | | - Pascal Jabbour
- Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
| | - Georgios Tsivgoulis
- Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | | | | | - Michael DeGeorgia
- University Hospital Cleveland Medical Center—Case Western Reserve University, Cleveland, Ohio
| | - Cathy A. Sila
- University Hospital Cleveland Medical Center—Case Western Reserve University, Cleveland, Ohio
| | - Nicholas Bambakidis
- University Hospital Cleveland Medical Center—Case Western Reserve University, Cleveland, Ohio
| | | | - Stephen M. Davis
- The Melbourne Brain Centre, Royal Melbourne Hospital and University of Melbourne, Melbourne, Victoria, Australia
| | | | | | - Marc Ribo
- Hospital Vall d’Hebrón, Barcelona, Spain
| | | | - Bruce C. Campbell
- The Melbourne Brain Centre, Royal Melbourne Hospital and University of Melbourne, Melbourne, Victoria, Australia
- Florey Institute for Neuroscience and Mental Health, Parkville, Victoria, Australia
| |
Collapse
|
3
|
Hevessy Z, Toth G, Antal-Szalmas P, Tokes-Fuzesi M, Kappelmayer J, Karai B, Ajzner E. Algorithm of differential diagnosis of anemia involving laboratory medicine specialists to advance diagnostic excellence. Clin Chem Lab Med 2024; 62:410-420. [PMID: 37823455 DOI: 10.1515/cclm-2023-0807] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Accepted: 10/03/2023] [Indexed: 10/13/2023]
Abstract
OBJECTIVES Anemia is a severe global public health issue. Testing practices for anemia suggest overuse of screening laboratory tests and misinterpretation of studies even in "easy-to-diagnose" underlying causes, leading to late diagnoses and missed treatment opportunities. We aimed to develop a complete and efficient algorithm for clinical pathologists and laboratory medicine physicians for the differential diagnosis of anemia. METHODS Comprehensive literature search encompassing original articles, studies, reviews, gold standard books, and other evidence. RESULTS We created a complex algorithm, primarily for clinical pathology/laboratory use, that explores all major and several rare causes of anemia in an efficient and evidence-based manner. The algorithm includes gold-standard diagnostic laboratory tests available in most clinical laboratories and indices that can be easily calculated to provide an evidence-based differential diagnosis of anemia. CONCLUSIONS The diagnostic strategy combines previously available diagnostic tests and protocols in an efficient order. Clinical pathologists following the algorithm can independently provide valuable diagnostic support for healthcare providers. Clinical pathologists providing complete differential diagnostic services with the proposed algorithm may create an opportunity for an advanced diagnostic service that supports diagnostic excellence and helps patients receive a timely diagnosis and early treatment opportunities.
Collapse
Affiliation(s)
- Zsuzsanna Hevessy
- Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
| | - Gabor Toth
- Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
| | - Peter Antal-Szalmas
- Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
| | - Margit Tokes-Fuzesi
- Department of Laboratory Medicine, University of Pecs, Medical School, Pecs, Hungary
| | - Janos Kappelmayer
- Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
| | - Bettina Karai
- Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
| | - Eva Ajzner
- Central Laboratory of Szabolcs-Szatmar-Bereg County Teaching Hospital, Nyiregyhaza, Hungary
- Hematology Unit of South-Pest Central Hospital and National Institute of Hematology and Infectology, Budapest, Hungary
| |
Collapse
|
4
|
Mierzwa AT, Nelson A, Kasab SA, Ortega Gutierrez S, Vivanco-Suarez J, Farooqui M, Jadhav AP, Desai S, Toth G, Alrohimi A, Nguyen TN, Klein P, Abdalkader M, Salahuddin H, Pandey A, Wilseck Z, Koduri S, Vora N, Aladamat N, Gharaibeh K, Afreen E, Al-Hajala H, Shawver J, Zaidi S, Jumaa M. Predictors of outcome and symptomatic intracranial hemorrhage in acute basilar artery occlusions: Analysis of the PC-SEARCH thrombectomy registry. Eur Stroke J 2024:23969873241234713. [PMID: 38403924 DOI: 10.1177/23969873241234713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2024] Open
Abstract
INTRODUCTION Recent randomized controlled trials demonstrated superiority of mechanical thrombectomy compared to medical therapy in acute basilar artery occlusions, however, little data is available to guide clinicians in functional prognosis and risk stratification. PATIENTS AND METHODS Data from the retrospectively established PC-SEARCH Thrombectomy registry, which included patients with basilar artery occlusion from eight sites from January 2015 to December 2021, was interrogated. Outcomes were dichotomized into 90-day favorable (mRS ⩽ 3) and unfavorable (mRS > 3). Multivariate logistic regression analysis was performed with respect to the outcome groups and were adjusted for potential confounding baseline characteristics. RESULTS Four-hundred-forty-four patients were included in this analysis. Mean age was 66 [SD 15], with 56% male, and comprised of 76% Caucasian. Patients presented with an initial median NIHSS of 18 and 199 patients (44.8%) achieved favorable 90-day functional outcomes. Independent predictors of favorable outcomes included younger age, pc-ASPECTS > 8 (OR 2.30 p < 0.001), and TICI ⩾ 2b (OR 7.56 p < 0.001). Unfavorable outcomes were associated with increasing number of passes (OR 1.29 p = 0.004) and sICH (OR 4.19 p = 0.015). IA-tPA was an independent risk factor for sICH (OR 7.15 p = 0.002) without improving favorable functional outcomes. CONCLUSION AND DISCUSSION PC-ASPECTS > 8, successful recanalization (TICI ⩾ 2b), first-pass recanalization, and younger age are independent predictors of favorable 90-day functional outcome in thrombectomy treated patients with acute basilar artery occlusion. Conversely, sICH were independent predictors of unfavorable outcomes. IA-tPA and unsuccessful recanalization are independently associated with sICH.
Collapse
Affiliation(s)
- Adam T Mierzwa
- Department of Neurology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA
- Promedica Stroke Network, Toledo, OH, USA
| | - Ashley Nelson
- Department of Neurology and Neurosurgery, Medical University of South Carolina, Charleston, SC, USA
| | - Sami Al Kasab
- Department of Neurology and Neurosurgery, Medical University of South Carolina, Charleston, SC, USA
| | | | | | | | - Ashutosh P Jadhav
- Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
| | - Shashvat Desai
- Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
| | - Gabor Toth
- Cleveland Clinic Foundation, Cleveland, OH, USA
| | | | - Thanh N Nguyen
- Department of Neurology, Radiology, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA
| | - Piers Klein
- Department of Neurology, Radiology, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA
| | - Mohamad Abdalkader
- Department of Neurology, Radiology, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA
| | - Hisham Salahuddin
- Department of Neurology, Antelope Valley Hospital, Los Angeles, CA, USA
| | - Aditya Pandey
- Department of Neurosurgery, University of Michigan, Ann Arbor, MI, USA
| | - Zachary Wilseck
- Department of Neurosurgery, University of Michigan, Ann Arbor, MI, USA
| | - Sravanthi Koduri
- Department of Neurosurgery, University of Michigan, Ann Arbor, MI, USA
| | - Niraj Vora
- Ohio Health Riverside Methodist Hospital, Columbus, OH, USA
| | - Nameer Aladamat
- Department of Neurology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA
| | - Khaled Gharaibeh
- Department of Neurology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA
| | - Ehad Afreen
- Department of Neurology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA
- Promedica Stroke Network, Toledo, OH, USA
| | - Hisham Al-Hajala
- Department of Neurology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA
| | | | - Syed Zaidi
- Department of Neurology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA
- Promedica Stroke Network, Toledo, OH, USA
| | - Mouhammad Jumaa
- Department of Neurology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA
- Promedica Stroke Network, Toledo, OH, USA
| |
Collapse
|
5
|
Elfil M, Morsi RZ, Ghozy S, Elmashad A, Siddiqui A, Al-Bayati AR, Alaraj A, Brook A, Kam AW, Chatterjee AR, Patsalides A, Waldau B, Prestigiacomo CJ, Matouk C, Schirmer CM, Altschul D, Parrella DT, Toth G, Jindal G, Shaikh HA, Dolia JN, Fifi JT, Fraser JF, DO JT, Amuluru K, Kim LJ, Harrigan M, Amans MR, Kole M, Mokin M, Abraham M, Jumaa M, Janjua N, Zaidat O, Youssef PP, Khandelwal P, Wang QT, Grandhi R, Hanel R, Kellogg RT, Ortega-Gutierrez S, Sheth S, Nguyen TN, Szeder V, Hu YC, Yoo AJ, Tanweer O, Jankowitz B, Heit JJ, Williamson R, Kass-Hout T, Crowley RW, El-Ghanem M, Al-Mufti F. Factors Affecting Selection of TraineE for Neurointervention (FASTEN). Interv Neuroradiol 2024:15910199241232726. [PMID: 38389309 DOI: 10.1177/15910199241232726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2024] Open
Abstract
BACKGROUND AND IMPORTANCE Neurointervention is a very competitive specialty in the United States due to the limited number of training spots and the larger pool of applicants. The training standards are continuously updated to ensure solid training experiences. Factors affecting candidate(s) selection have not been fully established yet. Our study aims to investigate the factors influencing the selection process. METHODS A 52-question survey was distributed to 93 program directors (PDs). The survey consisted of six categories: (a) Program characteristics, (b) Candidate demographics, (c) Educational credentials, (d) Personal traits, (e) Research and extracurricular activities, and (f) Overall final set of characteristics. The response rate was 59.1%. As per the programs' characteristics, neurosurgery was the most involved specialty in running the training programs (69%). Regarding demographics, the need for visa sponsorship held the greatest prominence with a mean score of 5.9 [standard deviation (SD) 2.9]. For the educational credentials, being a graduate from a neurosurgical residency and the institution where the candidate's residency training is/was scored the highest [5.4 (SD = 2.9), 5.4 (SD = 2.5), respectively]. Regarding the personal traits, assessment by faculty members achieved the highest score [8.9 (SD = 1)]. In terms of research/extracurricular activities, fluency in English had the highest score [7.2 (SD = 1.9)] followed by peer-reviewed/PubMed-indexed publications [6.4 (SD = 2.2)]. CONCLUSION Our survey investigated the factors influencing the final decision when choosing the future neurointerventional trainee, including demographic, educational, research, and extracurricular activities, which might serve as valuable guidance for both applicants and programs to refine the selection process.
Collapse
Affiliation(s)
- Mohamed Elfil
- Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, USA
| | - Rami Z Morsi
- Department of Neurology, University of Chicago, Chicago, IL, USA
| | - Sherief Ghozy
- Department of Radiology, Mayo Clinic, Rochester, MN, USA
| | - Ahmed Elmashad
- Department of Neurology, Yale University, New Haven, CT, USA
| | - Adnan Siddiqui
- Neurosurgery and Radiology and Canon Stroke and Vascular Research Center, University of Buffalo, Buffalo, NY, USA
| | - Alhamza R Al-Bayati
- Department of Neurology and Neurosurgery, University of Pittsburg Medical Center, Pittsburg, PA, USA
| | - Ali Alaraj
- Department of Neurosurgery, University of Illinois, Chicago, IL, USA
| | - Allan Brook
- Department of Neurosurgery, Montefiore Medical Center and Children's Hospital at Montefiore (CHAM), Bronx, NY, USA
| | - Anthony W Kam
- Department of Radiology, Loyola University Medical Center, Stritch School of Medicine, Maywood, IL, USA
| | - Arindam Rano Chatterjee
- Interventional Neuroradiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO, USA
| | - Athos Patsalides
- Department of Neurosurgery, North Shore University Hospital, Donald and Barbara Zucker School of Medicine, Manhasset, NY, USA
| | - Ben Waldau
- Neurosurgery, University of California Davis, Sacramento, CA, USA
| | - Charles J Prestigiacomo
- Department of Neurological Surgery, College of Medicine, University of Cincinnati, Cincinnati, OH, USA
| | - Charles Matouk
- Department of Neurosurgery, Yale School of Medicine, New Haven, CT, USA
| | | | - David Altschul
- Department of Neurosurgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA
| | - David T Parrella
- Interventional Neurology, Ascension Saint Thomas Hospital West, Nashville, TN, USA
| | - Gabor Toth
- Cerebrovascular Center, Cleveland Clinic, Cleveland, OH, USA
| | - Gaurav Jindal
- Division of Interventional Neuroradiology, Department of Radiology, University of Maryland Medical Center, Baltimore, MD, USA
| | - Hamza A Shaikh
- Department of Radiology, Cooper University Hospital, Camden, NJ, USA
| | | | - Johanna T Fifi
- Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Justin F Fraser
- Department of Neurological Surgery, University of Kentucky, Lexington, KY, USA
| | - Justin Thomas DO
- Department of Neurosurgery, McLaren Northern Hospital, Petoskey, MI, USA
| | - Krishna Amuluru
- Interventional Neuroradiology, Goodman Campbell Brain and Spine, Indianapolis, IN, USA
| | - Louis J Kim
- Department of Neurological Surgery, University of Washington, Seattle, WA, USA
| | - Mark Harrigan
- Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Matthew R Amans
- Departments of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA
| | - Max Kole
- Department of Neurosurgery, Henry Ford Hospital, Detroit, MI, USA
| | - Max Mokin
- Neurosurgery, University of South Florida, Tampa, FL, USA
| | - Michael Abraham
- Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA
| | - Mouhammad Jumaa
- Department of Neurology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA
| | - Nazli Janjua
- Asia Pacific Comprehensive Stroke Institute, Pomona Valley Hospital Medical Center, Pomona, CA, USA
| | - Osama Zaidat
- Department of Endovascular Neurosurgery, Mercy Health St Vincent Medical Center, Toledo, OH, USA
| | - Patrick P Youssef
- Department of Neurosurgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - Priyank Khandelwal
- Department of Neurosurgery, Rutgers New Jersey Medical School, Newark, NJ, USA
| | - Qingliang Tony Wang
- Departments of Neurology/Neurosurgery, Maimonides Medical Center/SUNY Downstate Health Sciences University, Brooklyn, NY, USA
| | - Ramesh Grandhi
- Department of Neurosurgery, Clinical Neuroscience Center, University of Utah, Salt Lake City, UT, USA
| | - Ricardo Hanel
- Lyerly Neurosurgery, Baptist Medical Center Downtown, Jacksonville, FL, USA
| | - Ryan T Kellogg
- Department of Neurosurgery, University of Virginia, Charlottesville, VA, USA
| | | | - Sunil Sheth
- Department of Neurology, McGovern Medical School at UTHealth, Houston, TX, USA
| | - Thanh N Nguyen
- Department of Neurology, Boston Medical Center, Boston, MA, USA
| | - Viktor Szeder
- Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
| | - Yin C Hu
- Department of Neurosurgery, UH Cleveland Medical Center, Cleveland, OH, USA
| | - Albert J Yoo
- Department of Radiology/Neurointervention, Texas Stroke Institute, Dallas-Fort Worth, TX, USA
| | - Omar Tanweer
- Neurosurgery, Baylor College of Medicine, Houston, TX, USA
| | | | - Jeremy J Heit
- Department of Interventional Neuroradiology, Stanford Medical Center, Palo Alto, CA, USA
| | - Richard Williamson
- Department of Neurological Surgery, Allegheny Health Network, Pittsburgh, PA, USA
| | - Tareq Kass-Hout
- Department of Neurology, University of Chicago, Chicago, IL, USA
| | - Richard W Crowley
- Department of Neurological Surgery, Rush University Medical Center, Chicago, IL, USA
| | - Mohammad El-Ghanem
- Neuroendovascular Surgery, HCA Houston Northwest/University of Houston College of Medicine, Houston, TX, USA
| | - Fawaz Al-Mufti
- Department of Neurosurgery, Westchester Medical Center, Valhalla, NY, USA
| |
Collapse
|
6
|
Kashkoush A, El-Abtah ME, Davison MA, Toth G, Moore N, Bain M. Repeat Flow Diversion for Retreatment of Incompletely Occluded Large Complex Symptomatic Cerebral Aneurysms: A Retrospective Case Series. Oper Neurosurg (Hagerstown) 2024:01787389-990000000-01027. [PMID: 38251895 DOI: 10.1227/ons.0000000000001056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2023] [Accepted: 12/01/2023] [Indexed: 01/23/2024] Open
Abstract
BACKGROUND AND OBJECTIVES Data regarding radiographic occlusion rates after repeat flow diversion after initial placement of a flow diverter (FD) in large intracranial aneurysms are limited. We report clinical and angiographic outcomes on 7 patients who required retreatment with overlapping FDs after initial flow diversion for large intracranial aneurysms. METHODS We performed a retrospective review of a prospectively maintained database of cerebrovascular procedures performed at our institution from 2017 to 2021. We identified patients who underwent retreatment with overlapping FDs for large (>10 mm) cerebral aneurysms after initial flow diversion. At last angiographic follow-up, occlusion grade was evaluated using the O'Kelly-Marotta (OKM) grading scale. RESULTS Seven patients (median age 57 years) with cerebral aneurysms requiring retreatment were identified. The most common aneurysm location was the ophthalmic internal carotid artery (n = 3) and basilar trunk (n = 3). There were 4 fusiform and 3 saccular aneurysms. The median aneurysm width was 18 mm; the median neck size for saccular aneurysms was 7 mm; and the median dome-to-neck ratio was 2.8. The median time to retreatment was 9 months, usually due to symptomatic mass effect. After retreatment, the median clinical follow-up was 36 months, MRI/magnetic resonance angiography follow-up was 15 months, and digital subtraction angiography follow-up was 14 months. Aneurysm occlusion at last angiographic follow-up was graded as OKM A (total filling, n = 1), B (subtotal filling, n = 2), C (early neck remnant, n = 3), and D (no filling, n = 0). All patients with symptomatic improvement were OKM C, whereas patients with worsened symptom burden were OKM A or B. Two patients required further open surgical management for definitive management of the aneurysm remnant. CONCLUSION Although most patients demonstrated a decrease in aneurysm remnant size, many had high-grade persistent filling (OKM grades A or B) in this subset of mostly large fusiform aneurysms. Larger studies with longer follow-up are warranted to optimize treatment strategies for atypical aneurysm remnants after repeat flow diversion.
Collapse
Affiliation(s)
- Ahmed Kashkoush
- Department of Neurological Surgery, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA
- Cerebrovascular Center, Cleveland Clinic Foundation, Cleveland, Ohio, USA
| | - Mohamed E El-Abtah
- Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
| | - Mark A Davison
- Department of Neurological Surgery, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA
- Cerebrovascular Center, Cleveland Clinic Foundation, Cleveland, Ohio, USA
| | - Gabor Toth
- Cerebrovascular Center, Cleveland Clinic Foundation, Cleveland, Ohio, USA
- Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA
| | - Nina Moore
- Department of Neurological Surgery, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA
- Cerebrovascular Center, Cleveland Clinic Foundation, Cleveland, Ohio, USA
| | - Mark Bain
- Department of Neurological Surgery, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA
- Cerebrovascular Center, Cleveland Clinic Foundation, Cleveland, Ohio, USA
| |
Collapse
|
7
|
Alrohimi A, Achey RL, Thompson N, Abdalla RN, Patterson T, Moazeni Y, Rasmussen PA, Toth G, Bain MD, Ansari SA, Hussain SM, Moore NZ. Treatment outcomes for ARUBA-eligible brain arteriovenous malformations: a comparison of real-world data from the NVQI-QOD AVM registry with the ARUBA trial. J Neurointerv Surg 2024:jnis-2023-020525. [PMID: 38195249 DOI: 10.1136/jnis-2023-020525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2023] [Accepted: 12/03/2023] [Indexed: 01/11/2024]
Abstract
BACKGROUND Significant controversy exists about the management of unruptured cerebral arteriovenous malformations (AVMs). Results from A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA) suggested that intervention increases the risk of stroke/death compared with medical management. However, numerous study limitations raised concerns about the trial's generalizability. OBJECTIVE To assess the rate of stroke/death and functional outcomes in ARUBA-eligible patients from a multicenter database, the Neurovascular Quality Initiative-Quality Outcomes Database (NVQI-QOD). METHODS We performed a retrospective analysis of prospectively collected data of ARUBA-eligible patients who underwent intervention at 18 participating centers. The primary endpoint was stroke/death from any cause. Secondary endpoints included neurologic, systemic, radiographic, and functional outcomes. RESULTS 173 ARUBA-eligible patients underwent intervention with median follow-up of 269 (25-722.5) days. Seventy-five patients received microsurgery±embolization, 37 received radiosurgery, and 61 received embolization. Baseline demographics, risk factors, and general AVM characteristics were similar between groups. A total of 15 (8.7%) patients experienced stroke/death with no significant difference in primary outcome between treatment modalities. Microsurgery±embolization was more likely to achieve AVM obliteration (P<0.001). Kaplan-Meier survival curves demonstrated no difference in overall death/stroke outcomes between the different treatment modalities' 5-year period (P=0.087). Additionally, when compared with the ARUBA interventional arm, our patients were significantly less likely to experience death/stroke (8.7% vs 30.7%; P<0.001) and functional impairment (mRS score ≥2 25.4% vs 46.2%; P<0.01). CONCLUSION Our results suggest that intervention for unruptured brain AVMs at comprehensive stroke centers across the United States is safe.
Collapse
Affiliation(s)
- Anas Alrohimi
- Cerebrovascular Center, Departments of Neurology and Neurosurgery, Neurological Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
- Department of Medicine (Neurology), King Saud University, Riyadh, Riyadh Province, Saudi Arabia
| | - Rebecca L Achey
- Cerebrovascular Center, Departments of Neurology and Neurosurgery, Neurological Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
| | - Nicolas Thompson
- Department of Quantitative Health Sciences (NRT), Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
| | - Ramez N Abdalla
- Department of Radiology, Neurology, and Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
| | - Thomas Patterson
- Cerebrovascular Center, Departments of Neurology and Neurosurgery, Neurological Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
| | - Yasaman Moazeni
- Department of Radiology, Neurology, and Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
| | - Peter A Rasmussen
- Cerebrovascular Center, Departments of Neurology and Neurosurgery, Neurological Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
| | - Gabor Toth
- Cerebrovascular Center, Departments of Neurology and Neurosurgery, Neurological Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
| | - Mark D Bain
- Cerebrovascular Center, Departments of Neurology and Neurosurgery, Neurological Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
| | - Sameer A Ansari
- Department of Radiology, Neurology, and Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
| | - Shazam M Hussain
- Cerebrovascular Center, Departments of Neurology and Neurosurgery, Neurological Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
| | - Nina Z Moore
- Cerebrovascular Center, Departments of Neurology and Neurosurgery, Neurological Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
| |
Collapse
|
8
|
Fazekas LA, Szabo B, Szegeczki V, Filler C, Varga A, Godo ZA, Toth G, Reglodi D, Juhasz T, Nemeth N. Impact Assessment of Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) and Hemostatic Sponge on Vascular Anastomosis Regeneration in Rats. Int J Mol Sci 2023; 24:16695. [PMID: 38069018 PMCID: PMC10706260 DOI: 10.3390/ijms242316695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2023] [Revised: 11/20/2023] [Accepted: 11/21/2023] [Indexed: 12/18/2023] Open
Abstract
The proper regeneration of vessel anastomoses in microvascular surgery is crucial for surgical safety. Pituitary adenylate cyclase-activating polypeptide (PACAP) can aid healing by decreasing inflammation, apoptosis and oxidative stress. In addition to hematological and hemorheological tests, we examined the biomechanical and histological features of vascular anastomoses with or without PACAP addition and/or using a hemostatic sponge (HS). End-to-end anastomoses were established on the right femoral arteries of rats. On the 21st postoperative day, femoral arteries were surgically removed for evaluation of tensile strength and for histological and molecular biological examination. Effects of PACAP were also investigated in tissue culture in vitro to avoid the effects of PACAP degrading enzymes. Surgical trauma and PACAP absorption altered laboratory parameters; most notably, the erythrocyte deformability decreased. Arterial wall thickness showed a reduction in the presence of HS, which was compensated by PACAP in both the tunica media and adventitia in vivo. The administration of PACAP elevated these parameters in vitro. In conclusion, the application of the neuropeptide augmented elastin expression while HS reduced it, but no significant alterations were detected in collagen type I expression. Elasticity and tensile strength increased in the PACAP group, while it decreased in the HS decreased. Their combined use was beneficial for vascular regeneration.
Collapse
Affiliation(s)
- Laszlo Adam Fazekas
- Department of Operative Techniques and Surgical Research, Faculty of Medicine, University of Debrecen, Moricz Zsigmond ut 22, H-4032 Debrecen, Hungary; (L.A.F.); (B.S.); (A.V.)
| | - Balazs Szabo
- Department of Operative Techniques and Surgical Research, Faculty of Medicine, University of Debrecen, Moricz Zsigmond ut 22, H-4032 Debrecen, Hungary; (L.A.F.); (B.S.); (A.V.)
| | - Vince Szegeczki
- Department of Anatomy, Histology and Embryology, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, H-4032 Debrecen, Hungary; (V.S.); (C.F.); (T.J.)
| | - Csaba Filler
- Department of Anatomy, Histology and Embryology, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, H-4032 Debrecen, Hungary; (V.S.); (C.F.); (T.J.)
| | - Adam Varga
- Department of Operative Techniques and Surgical Research, Faculty of Medicine, University of Debrecen, Moricz Zsigmond ut 22, H-4032 Debrecen, Hungary; (L.A.F.); (B.S.); (A.V.)
| | - Zoltan Attila Godo
- Department of Information Technology, Faculty of Informatics, University of Debrecen, Kassai ut 26, H-4028 Debrecen, Hungary;
| | - Gabor Toth
- Department of Medical Chemistry, Albert Szent-Györgyi Medical School, University of Szeged, Dom ter 8, H-6720 Szeged, Hungary;
| | - Dora Reglodi
- HUN-REN-PTE PACAP Research Group, Department of Anatomy, Medical School, University of Pecs, Szigeti ut 12, H-7624 Pecs, Hungary;
| | - Tamas Juhasz
- Department of Anatomy, Histology and Embryology, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, H-4032 Debrecen, Hungary; (V.S.); (C.F.); (T.J.)
| | - Norbert Nemeth
- Department of Operative Techniques and Surgical Research, Faculty of Medicine, University of Debrecen, Moricz Zsigmond ut 22, H-4032 Debrecen, Hungary; (L.A.F.); (B.S.); (A.V.)
| |
Collapse
|
9
|
Elfil M, Ghaith HS, Bayoumi A, Elmashad A, Aladawi M, Al-Ani M, Najdawi Z, Mammadli G, Russo B, Toth G, Nour M, Asif K, Nguyen TN, Gandhi CD, Kaur G, Hussain MS, Czap AL, El-Ghanem M, Mansour OY, Khandelwal P, Mayer S, Al-Mufti F. Impact of pre-treatment cerebral microbleeds on the outcomes of endovascular thrombectomy: A systematic review and meta-analysis. J Stroke Cerebrovasc Dis 2023; 32:107324. [PMID: 37660553 DOI: 10.1016/j.jstrokecerebrovasdis.2023.107324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Revised: 08/18/2023] [Accepted: 08/21/2023] [Indexed: 09/05/2023] Open
Abstract
OBJECTIVE/AIM To investigate the effect of cerebral microbleeds (CMBs) on the functional and safety outcomes of endovascular thrombectomy (EVT) in patients with acute ischemic stroke (AIS) due to large vessel occlusion (LVO). METHODS This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines for systematic review and meta-analysis. We included observational studies that recruited AIS-LVO patients, used susceptibility-sensitive magnetic resonance imaging (MRI) to detect CMBs, and examined the association between them and predefined outcome events. The extracted data included study and population characteristics, risk of bias domains, and outcome measures. The outcomes of interest included functional independence, revascularization success, procedural and hemorrhagic adverse events. We conducted a meta-analysis using the Mantel-Haenszel method and calculated the risk ratios. RESULTS Four studies with a total of 1,514 patients were included. A significant reduction in the likelihood of achieving a favorable functional outcome was observed in patients with CMBs (Risk ratio (RR) 0.69, 95% confidence interval (CI): 0.52 to 0.91, P=0.01). No significant differences were observed between the CMBs and no CMBs groups in terms of successful revascularization, mortality, intracranial hemorrhage (ICH), subarachnoid hemorrhage (SAH), and parenchymal hematoma. CONCLUSIONS The presence of CMBs significantly reduced the likelihood of achieving functional independence post-EVT in AIS-LVO patients. However, CMBs did not impact the rates of successful revascularization, mortality, or the occurrence of various hemorrhagic events. Future research should explore the mechanisms of this association and strategies to mitigate its impact.
Collapse
Affiliation(s)
- Mohamed Elfil
- Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, USA
| | | | - Ahmed Bayoumi
- Department of Neurology, McGovern Medical School, UTHealth, Houston, TX, USA
| | - Ahmed Elmashad
- Department of Neurology, Yale University, New Haven, CT, USA
| | - Mohammad Aladawi
- Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, USA
| | - Mina Al-Ani
- Department of Radiology, SUNY Downstate Health Sciences University, Brooklyn, NY, USA
| | - Zaid Najdawi
- Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, USA
| | - Gular Mammadli
- Department of Neurology, Westchester Medical Center, Valhalla, NY, USA
| | - Brittany Russo
- Department of Neurology, Westchester Medical Center, Valhalla, NY, USA
| | - Gabor Toth
- Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA
| | - May Nour
- Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
| | - Kaiz Asif
- Ascension Health and University of Illinois-Chicago, Chicago, IL, USA
| | - Thanh N Nguyen
- Department of Neurology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA
| | - Chirag D Gandhi
- Department of Neurosurgery, Westchester Medical Center, Valhalla, NY, USA
| | - Gurmeen Kaur
- Department of Neurosurgery, Westchester Medical Center, Valhalla, NY, USA
| | - M Shazam Hussain
- Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Alexandra L Czap
- Department of Neurology, McGovern Medical School, UTHealth, Houston, TX, USA
| | - Mohammad El-Ghanem
- Neuroendovascular Surgery, HCA Houston Northwest/University of Houston College of Medicine, Houston, TX, USA
| | - Ossama Yassin Mansour
- Department of Neurology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
| | - Priyank Khandelwal
- Department of Neurosurgery, Rutgers New Jersey Medical School, Newark, NJ, USA
| | - Stephan Mayer
- Department of Neurology, Westchester Medical Center, Valhalla, NY, USA
| | - Fawaz Al-Mufti
- Department of Neurosurgery, Westchester Medical Center, Valhalla, NY, USA.
| |
Collapse
|
10
|
Mierzwa AT, Al Kasab S, Nelson A, Ortega Gutierrez S, Vivanco-Suarez J, Farooqui M, Jadhav AP, Desai S, Toth G, Alrohimi A, Nguyen TN, Klein P, Abdalkader M, Salahuddin H, Pandey A, Koduri S, Vora N, Aladamat N, Gharaibeh K, Afreen E, Zaidi S, Jumaa M. Comparing Functional Outcomes and Safety Profiles of First-Line Aspiration Thrombectomy Versus Stentriever for Acute Basilar Artery Occlusion: Propensity Analysis of the PC-SEARCH Thrombectomy Registry. Stroke 2023; 54:2512-2521. [PMID: 37747965 DOI: 10.1161/strokeaha.123.043579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Accepted: 08/03/2023] [Indexed: 09/27/2023]
Abstract
BACKGROUND Aspiration catheters (ASPs) and stentriever thrombectomy devices have comparable safety and efficacy in anterior circulation ischemic strokes. However, there is lack of high-quality comparative data in acute basilar artery occlusions. Our objective is to compare the outcomes and safety of ASPs and stentriever devices in acute basilar artery occlusions. METHODS This is an analysis of the retrospectively established PC-SEARCH Thrombectomy (Posterior-Circulation Ischemic Stroke Evaluation: Analyzing Radiographic and Intraprocedural Predictors for Mechanical Thrombectomy) registry. Patients were dichotomized based on their first-line thrombectomy device (ASP and stentriever) and associated with their 90-day functional outcomes, intraprocedural metrics, and safety measures. Propensity analysis based on unequal baseline characteristics was performed. Consecutive patients with acute basilar artery occlusions who received mechanical thrombectomy were included from January 2015 to December 2021. Patients received either first-line contact aspiration or stentriever mechanical thrombectomy. Primary clinical and safety outcomes were 90-day functional independence measured by a modified Rankin Scale score of 0 to 3 and symptomatic intracranial hemorrhage, respectively. Secondary outcomes included puncture-recanalization times, first-pass recanalization rates, crossovers to other thrombectomy device, and neurological/hospital complications. RESULTS Five hundred eighteen patients were included in the registry, and a total of 383 patients were included (mean [SD] age, 65.5 [15] years; 228 [59%] men) in this analysis. Of these, 219 patients were first-line ASP while 164 patients received first-line stentriever devices. Median premorbid modified Rankin Scale was zero and median presenting National Institutes of Health Stroke Scale was 17 (interquartile range, 8-26). The proportion of favorable functional outcome was similar between the 2 techniques before (47.3% versus 42.5%; odds ratio, 1.22 [95% CI, 0.78-1.89]; P=0.38) and after propensity matching (odds ratio, 1.46 [95% CI, 0.85-2.49]; P=0.17). In our propensity-matched cohorts, puncture-recanalization times (18 versus 52 minutes; P<0.01) favored first-line ASP; however, first-pass recanalization rates (43.5% versus 44.5%; P=0.90) were similar between groups. First-line ASP was associated with higher rates of crossover (22% versus 6%; P<0.01), whereas stentriever was associated with higher rates of symptomatic intracranial hemorrhage (9.8% versus 3.4%; P=0.04). CONCLUSIONS First-line ASP and stentriever methods demonstrated similar functional outcome and recanalization rates. Stentriever methods were associated with higher rates of symptomatic intracranial hemorrhage, whereas ASPs were associated with higher rates of crossover to alternative technique in patients with acute basilar occlusions.
Collapse
Affiliation(s)
- Adam T Mierzwa
- Department of Neurology, University of Toledo College of Medicine and Life Sciences, OH (A.T.M., N.A., K.G., E.A., S.Z., M.J.)
- Promedica Stroke Network, Toledo, OH (A.T.M., E.A., S.Z., M.J.)
| | - Sami Al Kasab
- Department of Neurology and Neurosurgery, Medical University of South Carolina, Charleston (S.A.K., A.N.)
| | - Ashley Nelson
- Department of Neurology and Neurosurgery, Medical University of South Carolina, Charleston (S.A.K., A.N.)
| | | | | | | | - Ashutosh P Jadhav
- Department of Neurology, University of Pittsburgh Medical Center, PA (A.P.J., S.D.)
| | - Shashvat Desai
- Department of Neurology, University of Pittsburgh Medical Center, PA (A.P.J., S.D.)
| | - Gabor Toth
- Cleveland Clinic Foundation, OH (G.T., A.A.)
| | | | - Thanh N Nguyen
- Department of Neurology, Radiology, Boston University Chobanian and Avedisian School of Medicine, MA (T.N.N., P.K., M.A.)
| | - Piers Klein
- Department of Neurology, Radiology, Boston University Chobanian and Avedisian School of Medicine, MA (T.N.N., P.K., M.A.)
| | - Mohamad Abdalkader
- Department of Neurology, Radiology, Boston University Chobanian and Avedisian School of Medicine, MA (T.N.N., P.K., M.A.)
| | - Hisham Salahuddin
- Department of Neurology, Antelope Valley Hospital, Los Angeles, CA (H.S.)
| | - Aditya Pandey
- Department of Neurosurgery, University of Michigan, Ann Arbor (A.P., S.K.)
| | - Sravanthi Koduri
- Department of Neurosurgery, University of Michigan, Ann Arbor (A.P., S.K.)
| | - Niraj Vora
- Ohio Health Riverside Methodist Hospital, Columbus (N.V.)
| | - Nameer Aladamat
- Department of Neurology, University of Toledo College of Medicine and Life Sciences, OH (A.T.M., N.A., K.G., E.A., S.Z., M.J.)
| | - Khaled Gharaibeh
- Department of Neurology, University of Toledo College of Medicine and Life Sciences, OH (A.T.M., N.A., K.G., E.A., S.Z., M.J.)
| | - Ehad Afreen
- Department of Neurology, University of Toledo College of Medicine and Life Sciences, OH (A.T.M., N.A., K.G., E.A., S.Z., M.J.)
- Promedica Stroke Network, Toledo, OH (A.T.M., E.A., S.Z., M.J.)
| | - Syed Zaidi
- Department of Neurology, University of Toledo College of Medicine and Life Sciences, OH (A.T.M., N.A., K.G., E.A., S.Z., M.J.)
- Promedica Stroke Network, Toledo, OH (A.T.M., E.A., S.Z., M.J.)
| | - Mouhammad Jumaa
- Department of Neurology, University of Toledo College of Medicine and Life Sciences, OH (A.T.M., N.A., K.G., E.A., S.Z., M.J.)
- Promedica Stroke Network, Toledo, OH (A.T.M., E.A., S.Z., M.J.)
| |
Collapse
|
11
|
Patko E, Szabo E, Vaczy A, Molitor D, Tari E, Li L, Csutak A, Toth G, Reglodi D, Atlasz T. Protective Effects of Pituitary Adenylate-Cyclase-Activating Polypeptide on Retinal Vasculature and Molecular Responses in a Rat Model of Moderate Glaucoma. Int J Mol Sci 2023; 24:13256. [PMID: 37686074 PMCID: PMC10487862 DOI: 10.3390/ijms241713256] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2023] [Revised: 08/14/2023] [Accepted: 08/21/2023] [Indexed: 09/10/2023] Open
Abstract
Despite the high probability of glaucoma-related blindness, its cause is not fully understood and there is no efficient therapeutic strategy for neuroprotection. Vascular factors have been suggested to play an important role in glaucoma development and progression. Previously, we have proven the neuroprotective effects of pituitary adenylate-cyclase-activating polypeptide (PACAP) eye drops in an inducible, microbeads model in rats that is able to reproduce many clinically relevant features of human glaucoma. In the present study, we examined the potential protective effects of PACAP1-38 on the retinal vasculature and the molecular changes in hypoxia. Ocular hypertension was induced by injection of microbeads into the anterior chamber, while control rats received PBS. PACAP dissolved in vehicle (1 µg/drop) or vehicle treatment was started one day after the injections for four weeks three times a day. Retinal degeneration was assessed with optical coherence tomography (OCT), and vascular and molecular changes were assessed by immunofluorescence labeling. HIF1-α and VEGF-A protein levels were measured by Western blot. OCT images proved severe retinal degeneration in the glaucomatous group, while PACAP1-38 eye drops had a retinoprotective effect. Vascular parameters were deteriorated and molecular analysis suggested hypoxic conditions in glaucoma. PACAP treatment exerted a positive effect against these alterations. In summary, PACAP could prevent the severe damage to the retina and its vasculature induced by ocular hypertension in a microbeads model.
Collapse
Affiliation(s)
- Evelin Patko
- Department of Anatomy, ELKH-PTE PACAP Research Team, Medical School, University of Pecs, 7624 Pecs, Hungary
| | - Edina Szabo
- Department of Anatomy, ELKH-PTE PACAP Research Team, Medical School, University of Pecs, 7624 Pecs, Hungary
| | - Alexandra Vaczy
- Department of Anatomy, ELKH-PTE PACAP Research Team, Medical School, University of Pecs, 7624 Pecs, Hungary
| | - Dorottya Molitor
- Department of Anatomy, ELKH-PTE PACAP Research Team, Medical School, University of Pecs, 7624 Pecs, Hungary
| | - Eniko Tari
- Department of Anatomy, ELKH-PTE PACAP Research Team, Medical School, University of Pecs, 7624 Pecs, Hungary
| | - Lina Li
- Department of Anatomy, ELKH-PTE PACAP Research Team, Medical School, University of Pecs, 7624 Pecs, Hungary
| | - Adrienne Csutak
- Department of Ophthalmology, Clinical Centre, Medical School, University of Pecs, 7632 Pecs, Hungary
| | - Gabor Toth
- Department of Medical Chemistry, Albert Szent-Györgyi Medical School, University of Szeged, 6720 Szeged, Hungary
- MTA-SZTE Biomimetic Systems Research Group, Albert Szent-Györgyi Medical School, University of Szeged, 6720 Szeged, Hungary
| | - Dora Reglodi
- Department of Anatomy, ELKH-PTE PACAP Research Team, Medical School, University of Pecs, 7624 Pecs, Hungary
| | - Tamas Atlasz
- Department of Anatomy, ELKH-PTE PACAP Research Team, Medical School, University of Pecs, 7624 Pecs, Hungary
- Department of Sportbiology, Faculty of Sciences, University of Pecs, 7624 Pecs, Hungary
| |
Collapse
|
12
|
Kashkoush A, El-Abtah ME, Petitt JC, Glauser G, Winkelman R, Achey RL, Davison M, Abdulrazzak MA, Hussain SM, Toth G, Bain M, Moore N. Flow diversion for the treatment of intracranial bifurcation aneurysms: a systematic review and meta-analysis. J Neurointerv Surg 2023:jnis-2023-020582. [PMID: 37541838 DOI: 10.1136/jnis-2023-020582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Accepted: 07/19/2023] [Indexed: 08/06/2023]
Abstract
BACKGROUND Flow diversion (FD: flow diversion, flow diverter) is an endovascular treatment for many intracranial aneurysm types; however, limited reports have explored the use of FDs in bifurcation aneurysm management. We analyzed the safety and efficacy of FD for the management of intracranial bifurcation aneurysms. METHODS A systematic review identified original research articles that used FD for treating intracranial bifurcation aneurysms. Articles with >4 patients that reported outcomes on the use of FDs for the management of bifurcation aneurysms along the anterior communicating artery (AComA), internal carotid artery terminus (ICAt), basilar apex (BA), or middle cerebral artery bifurcation (MCAb) were included. Meta-analysis was performed using a random effects model. RESULTS 19 studies were included with 522 patients harboring 534 bifurcation aneurysms (mean size 9 mm, 78% unruptured). Complete aneurysmal occlusion rate was 68% (95% CI 58.7% to 76.1%, I2=67%) at mean angiographic follow-up of 16 months. Subgroup analysis of FD as a standalone treatment estimated a complete occlusion rate of 69% (95% CI 50% to 83%, I2=38%). The total complication rate was 22% (95% CI 16.7% to 28.6%, I2=51%), largely due to an ischemic complication rate of 16% (95% CI 10.8% to 21.9%, I2=55%). The etiologies of ischemic complications were largely due to jailed artery hypoperfusion (47%) and in-stent thrombosis (38%). 7% of patients suffered permanent symptomatic complications (95% CI 4.5% to 9.8%, I2=6%). CONCLUSION FD treatment of bifurcation aneurysms has a modest efficacy and relatively unfavorable safety profile. Proceduralists may consider reserving FD as a treatment option if no other surgical or endovascular therapy is deemed feasible.
Collapse
Affiliation(s)
- Ahmed Kashkoush
- Department of Neurological Surgery, Cleveland Clinic, Cleveland, OH, USA
| | | | - Jordan C Petitt
- Case Western Reserve University School of Medicine, Cleveland, OH, USA
| | - Gregory Glauser
- Department of Neurological Surgery, Cleveland Clinic, Cleveland, OH, USA
| | - Robert Winkelman
- Department of Neurological Surgery, Cleveland Clinic, Cleveland, OH, USA
| | - Rebecca L Achey
- Department of Neurological Surgery, Cleveland Clinic, Cleveland, OH, USA
| | - Mark Davison
- Department of Neurological Surgery, Cleveland Clinic, Cleveland, OH, USA
| | - Mohammad A Abdulrazzak
- Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA
- Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Shazam M Hussain
- Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA
- Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Gabor Toth
- Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA
- Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Mark Bain
- Department of Neurological Surgery, Cleveland Clinic, Cleveland, OH, USA
- Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Nina Moore
- Department of Neurological Surgery, Cleveland Clinic, Cleveland, OH, USA
- Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA
| |
Collapse
|
13
|
Elfil M, Ghozy S, Elmashad A, Ghaith HS, Aladawi M, Dicpinigaitis AJ, Mansour OY, Khandelwal P, Asif K, Nour M, Toth G, Al-Mufti F. Effect of intra-arterial thrombolysis following successful endovascular thrombectomy on functional outcomes in patients with large vessel occlusion acute ischemic stroke: A post-CHOICE meta-analysis. J Stroke Cerebrovasc Dis 2023; 32:107194. [PMID: 37216750 DOI: 10.1016/j.jstrokecerebrovasdis.2023.107194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2023] [Revised: 05/16/2023] [Accepted: 05/17/2023] [Indexed: 05/24/2023] Open
Abstract
INTRODUCTION Endovascular thrombectomy (EVT) is the standard treatment of acute ischemic stroke (AIS) due to large vessel occlusion (LVO). Although > 70% of patients in the trials assessing EVT for AIS-LVO had successful recanalization, only a third ultimately achieved favorable outcomes. A "no-reflow" phenomenon due to distal microcirculation disruption might contribute to such suboptimal outcomes. Combining intra-arterial (IA) tissue plasminogen activator (tPA) and EVT to reduce the distal microthrombi burden was investigated in a few studies. We present a pooled-data meta-analysis of the existing evidence of this combinatorial treatment. METHODS We followed the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) recommendations. We aimed to include all original studies investigating EVT plus IA tPA in AIS-LVO patients. Using R software, we calculated pooled odds ratios (ORs) with corresponding 95% confidence intervals (CI). A fixed-effects model was adopted to evaluate pooled data. RESULTS Five studies satisfied the inclusion criteria. Successful recanalization was comparable between the IA tPA and control groups at 82.9% and 82.32% respectively. The 90-day functional independence was similar between both groups (OR= 1.25; 95% CI= 0.92-1.70; P= 0.154). Symptomatic intracranial hemorrhage (sICH) was also comparable between both groups (OR= 0.66; 95% CI= 0.34-1.26; P= 0.304). CONCLUSION Our current meta-analysis does not show significant differences between EVT alone and EVT plus IA tPA in terms of functional independence or sICH. However, with the limited number of studies and included patients, more randomized controlled trials (RCTs) are needed to further investigate the benefits and safety of combined EVT and IA tPA.
Collapse
Affiliation(s)
- Mohamed Elfil
- Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, USA
| | - Sherief Ghozy
- Department of Radiology, Mayo Clinic, Rochester, MN, USA
| | - Ahmed Elmashad
- Department of Neurology, University of Connecticut, Farmington, CT, USA
| | | | - Mohammad Aladawi
- Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, USA
| | | | - Ossama Yassin Mansour
- Department of Neurology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
| | - Priyank Khandelwal
- Department of Neurosurgery, Rutgers New Jersey Medical School, Newark, NJ, USA
| | - Kaiz Asif
- Ascension Health and University of Illinois-Chicago, Chicago, IL, USA
| | - May Nour
- Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
| | - Gabor Toth
- Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Fawaz Al-Mufti
- Department of Neurology and Neurosurgery, New York Medical College at Westchester Medical Center, Valhalla, NY, USA.
| |
Collapse
|
14
|
Rodriguez-Calienes A, Galecio-Castillo M, Vivanco-Suarez J, Mohamed GA, Toth G, Sarraj A, Pujara D, Chowdhury AA, Farooqui M, Ghannam M, Samaniego EA, Jovin TG, Ortega-Gutierrez S. Endovascular thrombectomy beyond 24 hours from last known well: a systematic review with meta-analysis. J Neurointerv Surg 2023:jnis-2023-020443. [PMID: 37355251 DOI: 10.1136/jnis-2023-020443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2023] [Accepted: 06/04/2023] [Indexed: 06/26/2023]
Abstract
BACKGROUND Different studies have demonstrated the benefit of endovascular treatment (EVT) up to 24 hours after acute ischemic stroke (AIS) onset. Recent cohort observational studies suggest that patients with large vessel occlusion AIS may benefit from EVT beyond 24 hours from the last known well (LKW) when adequately selected. We aimed to examine the safety and efficacy of EVT beyond 24 hours from LKW using a meta-analysis of all the literature available. METHODS A systematic search from inception to April 2023 was conducted for studies including AIS patients with EVT beyond 24 hours from LKW in Medline, Embase, Scopus, and Web of Science. Outcomes of interest included favorable functional outcome (90-day modified Rankin scale (mRS) 0-2), successful reperfusion (modified Thrombolysis in Cerebral Infarction (mTICI) 2b-3), symptomatic intracerebral hemorrhage (sICH), and 90-day mortality. Data were pooled using a random-effects model. RESULTS Twelve studies with 894 patients were included. The rate of favorable functional outcome was 40% (95% CI 31% to 49%; I2=76%). The rate of successful reperfusion was 83% (95% CI 80% to 85%; I2=0%). The sICH rate was 7% (95% CI 5% to 9%; I2=0%) and the 90-day mortality rate was 28% (95% CI 24% to 33%; I2=0%). There was no significant difference in favorable outcomes (OR=0.69; 95% CI 0.41 to 1.14) and 90-day mortality (OR=1.35; 95% CI 0.90 to 2.00) among patients who underwent EVT <24 hours versus >24 hours. CONCLUSIONS EVT beyond 24 hours from LKW may achieve favorable clinical outcomes and high reperfusion rates, with acceptable intracranial hemorrhage rates in selected patients. Considering the current certainty of the evidence and heterogenous individual study results, larger prospective trials are warranted.
Collapse
Affiliation(s)
- Aaron Rodriguez-Calienes
- Department of Neurology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA
- Neuroscience, Clinical Effectiveness and Public Health Research Group, Universidad Científica del Sur, Lima, Peru
| | | | - Juan Vivanco-Suarez
- Department of Neurology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA
| | - Ghada A Mohamed
- Department of Neurology, Medical University of South Carolina, Charleston, South Carolina, USA
| | - Gabor Toth
- Cerebrovascular Center, Cleveland Clinic, Cleveland, Ohio, USA
| | - Amrou Sarraj
- Department of Neurology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA
| | - Deep Pujara
- Department of Neurology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA
| | - Aj A Chowdhury
- Department of Neurology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA
| | - Mudassir Farooqui
- Department of Neurology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA
| | - Malik Ghannam
- Department of Neurology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA
| | - Edgar A Samaniego
- Department of Neurology, Neurosurgery & Radiology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA
| | - Tudor G Jovin
- Cooper Neurological Institute, Cooper University Hospital, Camden, New Jersey, USA
| | - Santiago Ortega-Gutierrez
- Department of Neurology, Neurosurgery & Radiology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA
| |
Collapse
|
15
|
Haude M, Wlodarczak A, van der Schaaf RJ, Torzewski J, Ferdinande B, Escaned J, Iglesias JF, Bennett J, Toth G, Joner M, Toelg R, Wiemer M, Olivecrona G, Vermeersch P, Garcia-Garcia HM, Waksman R. Safety and performance of the third-generation drug-eluting resorbable coronary magnesium scaffold system in the treatment of subjects with de novo coronary artery lesions: 6-month results of the prospective, multicenter BIOMAG-I first-in-human study. EClinicalMedicine 2023; 59:101940. [PMID: 37113674 PMCID: PMC10126775 DOI: 10.1016/j.eclinm.2023.101940] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/29/2022] [Revised: 03/16/2023] [Accepted: 03/16/2023] [Indexed: 04/29/2023] Open
Abstract
Background A third-generation coronary drug-eluting resorbable magnesium scaffold (DREAMS 3G) was developed to enhance the performance of previous scaffold generations and achieve angiographic outcomes comparable to those of contemporary drug-eluting stents. Methods This prospective, multicenter, non-randomized, first-in-human study was conducted at 14 centers in Europe. Eligible patients had stable or unstable angina, documented silent ischemia, or non-ST-elevation myocardial infarction, and a maximum of two single de novo lesions in two separate coronary arteries with a reference vessel diameter between 2.5 mm and 4.2 mm. Clinical follow-up was scheduled at one, six and 12 months and annually thereafter until five years. Invasive imaging assessments were scheduled six and 12 months postoperatively. The primary endpoint was angiographic in-scaffold late lumen loss at six months. This trial was registered at ClinicalTrials.gov (NCT04157153). Findings Between April 2020 and February 2022, 116 patients with 117 coronary artery lesions were enrolled. At six months, in-scaffold late lumen loss was 0.21 mm (SD 0.31). Intravascular ultrasound assessment showed preservation of the scaffold area (mean 7.59 mm2 [SD 2.21] post-procedure vs 6.96 mm2 [SD 2.48]) at six months) with a low mean neointimal area (0.02 mm2 [SD 0.10]). Optical coherence tomography revealed that struts were embedded in the vessel wall and were already hardly discernible at six months. Target lesion failure occurred in one (0.9%) patient; a clinically driven target lesion revascularization was performed on post-procedure day 166. No definite or probable scaffold thrombosis or myocardial infarction was observed. Interpretation These findings show that the implantation of DREAMS 3G in de novo coronary lesions is associated with favorable safety and performance outcomes, comparable to contemporary drug-eluting stents. Funding This study was funded by BIOTRONIK AG.
Collapse
Affiliation(s)
- Michael Haude
- Medical Clinic I, Rheinland Klinikum Neuss GmbH, Lukaskrankenhaus, Neuss, Germany
- Corresponding author. Rheinland Klinikum Neuss GmbH, Lukaskrankenhaus, Preussenstr. 84, 41464, Neuss, Germany.
| | - Adrian Wlodarczak
- Department of Cardiology, Miedziowe Centrum Zdrowia SA, Lubin, Poland
| | | | | | - Bert Ferdinande
- Department of Cardiology, Ziekenhuis Oost Limburg (ZOL), Genk, Belgium
| | - Javier Escaned
- Division of Cardiology, Hospital Clinico San Carlos IDISSC, Complutense University of Madrid, Madrid, Spain
| | - Juan F. Iglesias
- Cardiology Division, University Hospital of Geneva, Geneva, Switzerland
| | - Johan Bennett
- Department of Cardiovascular Medicine, University Hospitals Leuven, Leuven, Belgium
| | - Gabor Toth
- Division Cardiology, Medical University Graz, Graz, Austria
| | - Michael Joner
- Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, München, Germany
- Deutsches Zentrum für Herz- und Kreislauf-Forschung (DZHK) e.V. (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany
| | - Ralph Toelg
- Cardiology Department, Heart Center Segeberger Kliniken, Bad Segeberg, Germany
| | - Marcus Wiemer
- Department of Cardiology and Intensive Care, Johannes Wesling University Hospital Ruhr University Bochum, Minden, Germany
| | - Göran Olivecrona
- Department of Cardiology, Skane University Hospital, Lund, Sweden
| | - Paul Vermeersch
- Interventional Cardiology ZNA Middelheim, Antwerpen, Belgium
| | | | - Ron Waksman
- Interventional Cardiology, MedStar Washington Hospital Center, Washington DC, USA
| |
Collapse
|
16
|
Asif KS, Otite FO, Desai SM, Herial N, Inoa V, Al-Mufti F, Jadhav AP, Dmytriw AA, Castonguay A, Khandelwal P, Potter-Vig J, Szeder V, Kulman T, Urrutia V, Masoud H, Toth G, Limaye K, Aroor S, Brinjikji W, Rai A, Pandian J, Gebreyohanns M, Leung T, Mansour O, Demchuk AM, Huded V, Martins S, Zaidat O, Huo X, Campbell B, Sylaja PN, Miao Z, Saver J, Ortega-Gutierrez S, Yavagal DR. Mechanical Thrombectomy Global Access For Stroke (MT-GLASS): A Mission Thrombectomy (MT-2020 Plus) Study. Circulation 2023; 147:1208-1220. [PMID: 36883458 DOI: 10.1161/circulationaha.122.063366] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/09/2023]
Abstract
BACKGROUND Despite the well-established potent benefit of mechanical thrombectomy (MT) for large vessel occlusion (LVO) stroke, access to MT has not been studied globally. We conducted a worldwide survey of countries on 6 continents to define MT access (MTA), the disparities in MTA, and its determinants on a global scale. METHODS Our survey was conducted in 75 countries through the Mission Thrombectomy 2020+ global network between November 22, 2020, and February 28, 2021. The primary end points were the current annual MTA, MT operator availability, and MT center availability. MTA was defined as the estimated proportion of patients with LVO receiving MT in a given region annually. The availability metrics were defined as ([current MT operators×50/current annual number of estimated thrombectomy-eligible LVOs]×100 = MT operator availability) and ([current MT centers×150/current annual number of estimated thrombectomy-eligible LVOs]×100= MT center availability). The metrics used optimal MT volume per operator as 50 and an optimal MT volume per center as 150. Multivariable-adjusted generalized linear models were used to evaluate factors associated with MTA. RESULTS We received 887 responses from 67 countries. The median global MTA was 2.79% (interquartile range, 0.70-11.74). MTA was <1.0% for 18 (27%) countries and 0 for 7 (10%) countries. There was a 460-fold disparity between the highest and lowest nonzero MTA regions and low-income countries had 88% lower MTA compared with high-income countries. The global MT operator availability was 16.5% of optimal and the MT center availability was 20.8% of optimal. On multivariable regression, country income level (low or lower-middle versus high: odds ratio, 0.08 [95% CI, 0.04-0.12]), MT operator availability (odds ratio, 3.35 [95% CI, 2.07-5.42]), MT center availability (odds ratio, 2.86 [95% CI, 1.84-4.48]), and presence of prehospital acute stroke bypass protocol (odds ratio, 4.00 [95% CI, 1.70-9.42]) were significantly associated with increased odds of MTA. CONCLUSIONS Access to MT on a global level is extremely low, with enormous disparities between countries by income level. The significant determinants of MT access are the country's per capita gross national income, prehospital LVO triage policy, and MT operator and center availability.
Collapse
Affiliation(s)
- Kaiz S Asif
- Ascension Health, Chicago, IL (K.S.A.).,University of Illinois, Chicago (K.S.A.)
| | - Fadar O Otite
- SUNY Upstate Medical University, Syracuse, NY (F.O.O.)
| | - Shashvat M Desai
- HonorHealth Research and Innovation Institute, Scottsdale, AZ (S.M.D.)
| | - Nabeel Herial
- Thomas Jefferson University, Philadelphia, PA (N.H.)
| | - Violiza Inoa
- Semmes-Murphey Neurologic and Spine Clinic, Memphis, TN (V.I.)
| | | | | | | | | | | | - Jennifer Potter-Vig
- Society of Vascular and Interventional Neurology/MT2020, Minneapolis, MN (J.P.-V.)
| | | | | | - Victor Urrutia
- Johns Hopkins University School of Medicine, Baltimore, MD (V.U.)
| | | | | | | | | | | | - Ansaar Rai
- West Virginia University, Morgantown (A.R.)
| | | | | | - Thomas Leung
- Prince of Wales Hospital, Randwick, Australia (T.L.)
| | | | | | - Vikram Huded
- NH Institute of Neurosciences, Bengaluru, Karnataka, India (V.H.)
| | - Sheila Martins
- University of Rio Grande do Sul, Porto Alegre, Brazil (S.M.)
| | - Osama Zaidat
- St Vincent Mercy Medical Center, Toledo, OH (O.Z.)
| | - Xiaochuan Huo
- Beijing Tiantan Hospital, Capital Medical University, Beijing, China (X.H., Z.M.)
| | - Bruce Campbell
- Royal Melbourne Hospital, University of Melbourne, Parkville, Australia (B.C.)
| | - P N Sylaja
- Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, India (P.N.S.)
| | - Zhongrong Miao
- Beijing Tiantan Hospital, Capital Medical University, Beijing, China (X.H., Z.M.)
| | | | | | | |
Collapse
|
17
|
Pandhi A, Chandra R, Abdulrazzak MA, Alrohimi A, Mahapatra A, Bain M, Moore N, Hussain MS, Bullen J, Toth G. Mechanical thrombectomy for acute large vessel occlusion stroke beyond 24 h. J Neurol Sci 2023; 447:120594. [PMID: 36893513 DOI: 10.1016/j.jns.2023.120594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2022] [Revised: 01/20/2023] [Accepted: 02/22/2023] [Indexed: 03/06/2023]
Abstract
BACKGROUND Multiple trials have shown that mechanical thrombectomy (MT) is superior to medical therapy. However, no robust evidence is available regarding MT beyond 24 h. In this study, we aimed to determine the safety and efficacy of endovascular stroke therapy in this late window. METHODS We conducted a retrospective study of prospectively collected data of patients who met extended window trial criteria, but underwent MT beyond 24 h. Safety and efficacy outcomes included symptomatic intracerebral hemorrhage (sICH), procedural complications, number of passes, successful recanalization (mTICI 2b - 3), delta (Δ) NIHSS (baseline-discharge), and favorable outcomes (mRS 0-2 at 90 days). RESULTS A total of 39 patients were included with a median age of 69 years (IQR 61.5, 73.5); 54% were females. Hypertension was present in 76% of patients; 23% were smokers. Half of the patients had M1 occlusion (48.7%). Median preprocedural NIHSS was 11 (IQR 7.0, 19.5). Successful revascularization was achieved in 87%; median number of passes was 2 (IQR 1.0, 3.0). Median ΔNIHSS was 3.0 (IQR -1.5, 8.0). Favorable outcome was achieved in 49% (95% CI: 34%-64%), and 95% were free of complications. A total of 3 patients (7.7%) had sICH. In an exploratory analysis, posterior circulation occlusion was associated with higher mRS at 90 days (OR: 14.7, p = 0.016). Favorable discharge facility was associated with lower mRS at 90 days (OR: 0.11, p = 0.004). CONCLUSIONS Our study showed comparable clinical outcomes of MT beyond 24 h compared to MT trials within 24 h in patients with favorable imaging profile, especially in anterior circulation occlusions.
Collapse
Affiliation(s)
- Abhi Pandhi
- Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Rahul Chandra
- Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA
| | | | - Anas Alrohimi
- Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Ashutosh Mahapatra
- Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Mark Bain
- Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Nina Moore
- Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA
| | - M Shazam Hussain
- Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Jennifer Bullen
- Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA
| | - Gabor Toth
- Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
| |
Collapse
|
18
|
Hanel RA, Cortez GM, Lopes DK, Nelson PK, Siddiqui AH, Jabbour P, Mendes Pereira V, István IS, Zaidat OO, Bettegowda C, Colby GP, Mokin M, Schirmer CM, Hellinger FR, Given C, Krings T, Taussky P, Toth G, Fraser JF, Chen M, Priest R, Kan P, Fiorella D, Frei D, Aagaard-Kienitz B, Diaz O, Malek AM, Cawley CM, Puri AS, Kallmes DF. Prospective study on embolization of intracranial aneurysms with the pipeline device (PREMIER study): 3-year results with the application of a flow diverter specific occlusion classification. J Neurointerv Surg 2023; 15:248-254. [PMID: 35292570 PMCID: PMC9985759 DOI: 10.1136/neurintsurg-2021-018501] [Citation(s) in RCA: 23] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Accepted: 02/06/2022] [Indexed: 11/03/2022]
Abstract
BACKGROUND The pipeline embolization device (PED; Medtronic) has presented as a safe and efficacious treatment for small- and medium-sized intracranial aneurysms. Independently adjudicated long-term results of the device in treating these lesions are still indeterminate. We present 3-year results, with additional application of a flow diverter specific occlusion scale. METHODS PREMIER (prospective study on embolization of intracranial aneurysms with pipeline embolization device) is a prospective, single-arm trial. Inclusion criteria were patients with unruptured wide-necked intracranial aneurysms ≤12 mm. Primary effectiveness (complete aneurysm occlusion) and safety (major neurologic event) endpoints were independently monitored and adjudicated. RESULTS As per the protocol, of 141 patients treated with a PED, 25 (17.7%) required angiographic follow-up after the first year due to incomplete aneurysm occlusion. According to the Core Radiology Laboratory review, three (12%) of these patients progressed to complete occlusion, with an overall rate of complete aneurysm occlusion at 3 years of 83.3% (115/138). Further angiographic evaluation using the modified Cekirge-Saatci classification demonstrated that complete occlusion, neck residual, or aneurysm size reduction occurred in 97.1%. The overall combined safety endpoint at 3 years was 2.8% (4/141), with only one non-debilitating major event occurring after the first year. There was one case of aneurysm recurrence but no cases of delayed rupture in this series. CONCLUSIONS The PED device presents as a safe and effective modality in treating small- and medium-sized intracranial aneurysms. The application of a flow diverter specific occlusion classification attested the long-term durability with higher rate of successful aneurysm occlusion and no documented aneurysm rupture. TRIAL REGISTRATION NCT02186561.
Collapse
Affiliation(s)
- Ricardo A Hanel
- Lyerly Neurosurgery, Baptist Neurological Institute, Jacksonville, Florida, USA
| | - Gustavo M Cortez
- Lyerly Neurosurgery, Baptist Neurological Institute, Jacksonville, Florida, USA
| | | | - Peter Kim Nelson
- Interventional Radiology, NYU Langone Medical Center, New York, New York, USA
| | - Adnan H Siddiqui
- Department of Neurosurgery, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA
| | - Pascal Jabbour
- Department of Neurosurgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA
| | - Vitor Mendes Pereira
- Division of Neuroradiology, Department of Medical Imaging and Division of Neurosurgery, Department of Surgery, Toronto Western Hospital, Toronto, Ontario, Canada
| | - Istvan Szikora István
- Department of Neuroradiology, National Institute of Neurosciences, Budapest, Hungary
| | - Osama O Zaidat
- Neuroscience Institute, Mercy Health Saint Vincent Medical Center, Toledo, Ohio, USA
| | - Chetan Bettegowda
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Geoffrey P Colby
- Department Neurosurgery, University of California Los Angeles, Los Angeles, California, USA
| | - Maxim Mokin
- Department of Neurosurgery, University of South Florida College of Medicine, Tampa, Florida, USA
| | - Clemens M Schirmer
- Department of Neurosurgery, Geisinger Health System, Danville, Pennsylvania, USA
| | - Frank R Hellinger
- Department of Radiology, Florida Hospital Neuroscience Institute, Winter Park, Florida, USA
| | - Curtis Given
- Department of Radiology, Baptist Health Lexington, Lexington, Kentucky, USA
| | - Timo Krings
- Department of Medical Imaging, Toronto Western Hospital, Toronto, Ontario, Canada
| | - Philipp Taussky
- Department of Neurosurgery, University of Utah Health, Salt Lake City, Utah, USA
| | - Gabor Toth
- Cerebrovascular Center, Cleveland Clinic, Cleveland, Ohio, USA
| | - Justin F Fraser
- Department of Neurological Surgery, University of Kentucky, Lexington, Kentucky, USA
| | - Michael Chen
- Department of Neurological Surgery, Rush University Medical Center, Chicago, Illinois, USA
| | - Ryan Priest
- Charles T Dotter Department of Interventional Radiology, Dotter Interventional Institute, Oregon Health and Science University, Portland, Oregon, USA
| | - Peter Kan
- Department of Neurosurgery, Baylor College of Medicine, Houston, Texas, USA
| | - David Fiorella
- Department of Neurosurgery, Cerebrovascular Center, Stony Brook University, Stony Brook, New York, USA
| | - Donald Frei
- Department of Neuroradiology, Swedish Medical Center, Englewood, Colorado, USA
| | - Beverly Aagaard-Kienitz
- Department of Neurological Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA
| | - Orlando Diaz
- Cerebrovascular Center, Houston Methodist Research Institute, Houston, Texas, USA
| | - Adel M Malek
- Department of Neurosurgery, Tufts Medical Center, Boston, Massachusetts, USA
| | - C Michael Cawley
- Department of Neurointerventional Radiology and Neurosurgery, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Ajit S Puri
- Department of Radiology, University of Massachusetts Medical School, Worcester, Massachusetts, USA
| | - David F Kallmes
- Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
| |
Collapse
|
19
|
Martucci M, Toth G, Buletko A, KHAWAJA Z, Russman AN, Hussain MS. Abstract WMP85: Mobile Stroke Unit: Direct To Angio Or Some Stops Along The Way? Stroke 2023. [DOI: 10.1161/str.54.suppl_1.wmp85] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Introduction:
Reducing the time from last known well to recanalization are associated with better functional outcomes and lower mortality in ischemic stroke. Recent data suggests that a “direct to angio” approach might improve the outcome of stroke patients with suspected emergent large vessel occlusion (ELVO). In this study, we aim to describe our direct-to-angiography vs those taken for additional imaging-first experience in our mobile stroke unit (MSU).
Methods:
Retrospective chart review from 2014 until 2022 was done. Patients with acute ischemic stroke due to ELVO arriving via MSU to our tertiary care comprehensive stroke center were included. We compared outcomes of those who went directly to the angiography suite versus those who underwent additional imaging studies first.
Results:
14 patients with ELVO went directly to angio (DTA group) compared to 52 patients who underwent additional imaging (CTA group). There were no differences in age, gender, pre-morbid vascular risk factors or presenting symptoms. The DTA group had a higher median initial NIHSS and a higher interquartile range when compared to the CTA group but not significant. The DTA group received more thrombolytic therapy compared to the CTA group (p = 0.03). The DTA group had better door-to-groin times (median 39 minutes) compared to the CTA group (median 51.5 minutes) (p = 0.02). TICI 0 - 2a was more frequently seen in the DTA group (35.7%) compared to the CTA group (9.6%) (p = 0.03). Mortality was significantly higher in the DTA group compared to the CTA group (35% vs. 9%; p = 0.028) but there was no difference in functional outcomes amongst groups (mRS 0 - 2 28% vs 17%; p = 0.45). There was a non-significantly higher incidence of tandem occlusions in the DTA group (28.5%) compared to the CTA group (28.5% vs. 15%; p = 0.43).
Conclusions:
In our analysis, those going direct to angiography from the MSU had less successful recanalization and increased mortality. These findings could also be related to the higher rate of tandem occlusions in the DTA group. Due to head only scanning being available on MSU, additional information from in-hospital scanning may offer other information which may influence selection of patients for the procedure. Further analysis of these paradigms, particularly on MSUs, are warranted.
Collapse
Affiliation(s)
- Maria Martucci
- Cerebrovascular Institute, Cleveland Clinic, Cleveland, OH
| | | | | | | | | | | |
Collapse
|
20
|
Pandhi A, Chandra R, Abdulrazzak M, Alrohimi A, Bain M, Moore N, Hussain M, Wadden D, Bullen J, Toth G. Abstract TP145: Mechanical Thrombectomy Beyond 24 Hours. Stroke 2023. [DOI: 10.1161/str.54.suppl_1.tp145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Background:
Multiple randomized controlled trials have shown that mechanical thrombectomy (MT) is superior to medical therapy. However, no robust evidence is available to assess the effectiveness of MT beyond the 24-hour window. In this study, we aimed to determine the safety and efficacy of MT in patients undergoing MT for stroke beyond 24 hours from last known normal (LKN).
Methods:
Retrospective review of a prospectively collected database for subjects who met extended window trial criteria, but underwent MT beyond 24 hours. Recorded variables included age, sex, NIHSS at baseline and at discharge, risk factors, level of occlusion, access site, thrombectomy method. Safety and efficacy outcomes included symptomatic intracerebral hemorrhage (sICH), procedural complications, number of passes, successful recanalization (TICI 2b-3), Δ NIHSS (baseline-discharge), favorable outcomes (mRS 0-2) at 90 days.
Results:
A total of 39 patients were included with a median age of 69 (IQR 61.5, 73.5); 54% were females. Hypertension was the most frequent risk factor in 76% of patients; 23 % of patients were smokers. Half of the patients had M1 occlusion (48.7%). Median preprocedural NIHSS was 11 (IQR 7.0, 19.5). Successful revascularization was achieved in 87%; median number of passes was 2 (IQR 1.0,3.0). Median ΔNIHSS was 3.0 (IQR -1.5, 8.0). Favorable outcome was achieved in 49% (95% CI: 34%-64%), and 95% were free of complications. A total of 3 patients (7.7%) had sICH. In an exploratory analysis, posterior circulation occlusion was associated with higher risk of poor mRS at 90 days (OR: 14.7, p = 0.016). Additionally, favorable discharge facility (home, home health, or rehab) was associated with a much lower risk of poor mRS at 90 days (OR: 0.11, p = 0.004).
Conclusions:
Our single center study of MT beyond 24 hours showed comparable clinical outcomes and safety profile to large MT trials within 24 hours, especially in anterior circulation occlusions. Posterior circulation occlusions were associated with worse outcomes, which warrants further investigation.
Collapse
|
21
|
Sarraj A, Albers GW, Mitchell PJ, Hassan AE, Abraham MG, Blackburn S, Sharma G, Yassi N, Kleinig TJ, Shah DG, Wu TY, Hussain MS, Tekle WG, Gutierrez SO, Aghaebrahim AN, Haussen DC, Toth G, Pujara D, Budzik RF, Hicks W, Vora N, Edgell RC, Slavin S, Lechtenberg CG, Maali L, Qureshi A, Rosterman L, Abdulrazzak MA, AlMaghrabi T, Shaker F, Mir O, Arora A, Martin-Schild S, Sitton CW, Churilov L, Gupta R, Lansberg MG, Nogueira RG, Grotta JC, Donnan GA, Davis SM, Campbell BCV. Thrombectomy Outcomes With General vs Nongeneral Anesthesia: A Pooled Patient-Level Analysis From the EXTEND-IA Trials and SELECT Study. Neurology 2023; 100:e336-e347. [PMID: 36289001 PMCID: PMC9869759 DOI: 10.1212/wnl.0000000000201384] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2022] [Accepted: 08/24/2022] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND AND OBJECTIVES The effect of anesthesia choice on endovascular thrombectomy (EVT) outcomes is unclear. Collateral status on perfusion imaging may help identify the optimal anesthesia choice. METHODS In a pooled patient-level analysis of EXTEND-IA, EXTEND-IA TNK, EXTEND-IA TNK part II, and SELECT, EVT functional outcomes (modified Rankin Scale score distribution) were compared between general anesthesia (GA) vs non-GA in a propensity-matched sample. Furthermore, we evaluated the association of collateral flow on perfusion imaging, assessed by hypoperfusion intensity ratio (HIR) - Tmax > 10 seconds/Tmax > 6 seconds (good collaterals - HIR < 0.4, poor collaterals - HIR ≥ 0.4) on the association between anesthesia type and EVT outcomes. RESULTS Of 725 treated with EVT, 299 (41%) received GA and 426 (59%) non-GA. The baseline characteristics differed in presentation National Institutes of Health Stroke Scale score (median [interquartile range] GA: 18 [13-22], non-GA: 16 [11-20], p < 0.001) and ischemic core volume (GA: 15.0 mL [3.2-38.0] vs non-GA: 9.0 mL [0.0-31.0], p < 0.001). In addition, GA was associated with longer last known well to arterial access (203 minutes [157-267] vs 186 minutes [138-252], p = 0.002), but similar procedural time (35.5 minutes [23-59] vs 34 minutes [22-54], p = 0.51). Of 182 matched pairs using propensity scores, baseline characteristics were similar. In the propensity score-matched pairs, GA was independently associated with worse functional outcomes (adjusted common odds ratio [adj. cOR]: 0.64, 95% CI: 0.44-0.93, p = 0.021) and higher neurologic worsening (GA: 14.9% vs non-GA: 8.9%, aOR: 2.10, 95% CI: 1.02-4.33, p = 0.045). Patients with poor collaterals had worse functional outcomes with GA (adj. cOR: 0.47, 95% CI: 0.29-0.76, p = 0.002), whereas no difference was observed in those with good collaterals (adj. cOR: 0.93, 95% CI: 0.50-1.74, p = 0.82), p interaction: 0.07. No difference was observed in infarct growth overall and in patients with good collaterals, whereas patients with poor collaterals demonstrated larger infarct growth with GA with a significant interaction between collaterals and anesthesia type on infarct growth rate (p interaction: 0.020). DISCUSSION GA was associated with worse functional outcomes after EVT, particularly in patients with poor collaterals in a propensity score-matched analysis from a pooled patient-level cohort from 3 randomized trials and 1 prospective cohort study. The confounding by indication may persist despite the doubly robust nature of the analysis. These findings have implications for randomized trials of GA vs non-GA and may be of utility for clinicians when making anesthesia type choice. CLASSIFICATION OF EVIDENCE This study provides Class III evidence that use of GA is associated with worse functional outcome in patients undergoing EVT. TRIAL REGISTRATION INFORMATION EXTEND-IA: ClinicalTrials.gov (NCT01492725); EXTEND-IA TNK: ClinicalTrials.gov (NCT02388061); EXTEND-IA TNK part II: ClinicalTrials.gov (NCT03340493); and SELECT: ClinicalTrials.gov (NCT02446587).
Collapse
Affiliation(s)
- Amrou Sarraj
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX.
| | - Gregory W Albers
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Peter J Mitchell
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Ameer E Hassan
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Michael G Abraham
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Spiros Blackburn
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Gagan Sharma
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Nawaf Yassi
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Timothy J Kleinig
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Darshan G Shah
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Teddy Y Wu
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Muhammad Shazam Hussain
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Wondwoseen G Tekle
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Santiago Ortega Gutierrez
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Amin Nima Aghaebrahim
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Diogo C Haussen
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Gabor Toth
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Deep Pujara
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Ronald F Budzik
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - William Hicks
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Nirav Vora
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Randall C Edgell
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Sabreena Slavin
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Colleen G Lechtenberg
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Laith Maali
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Abid Qureshi
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Lee Rosterman
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Mohammad Ammar Abdulrazzak
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Tareq AlMaghrabi
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Faris Shaker
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Osman Mir
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Ashish Arora
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Sheryl Martin-Schild
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Clark W Sitton
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Leonid Churilov
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Rishi Gupta
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Maarten G Lansberg
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Raul G Nogueira
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - James C Grotta
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Geoffrey Alan Donnan
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Stephen M Davis
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| | - Bruce C V Campbell
- From the Case Western Reserve University (A.S.), Neurology; University Hospitals Cleveland Medical Center (A.S., D.P.), Neurology, OH; Stanford University (G.W.A., M.G.L.), Neurology, CA; The Royal Melbourne Hospital - University of Melbourne (P.J.M.), Radiology, Parkville, Victoria, Australia; University of Texas Rio Grande Valley - Valley Baptist Medical Center (A.E.H., W.G.T.), Harlingen; University of Kansas Medical Center (M.G.A., S.S., C.G.L., L.M., A.Q., L.R.), Neurology and Radiology; UTHealth McGovern Medical School (S.B., F.S.), Neurosurgery, Houston TX; The Royal Melbourne Hospitals (G.S., N.Y., L.C., G.A.D., S.M.D., B.C.V.C.), University of Melbourne, Neurology; The Walter and Eliza Hall Institute of Medical Research (N.Y.), Population Health and Immunity, Parkville, Victoria; Royal Adelaide Hospital (T.J.K.), Neurology, Adelaide, South Australia; Gold Coast University Hospital (D.G.S.), Neurology, Southport, Queensland, Australia; Christchurch Hospital (T.Y.W.), Neurology, Christchurch, Canterbury, New Zealand; Cleveland Clinic (M.S.H., G.T., M.A.A.), Cerebrovascular Unit, OH; University of Iowa Hospitals (S.O.G.), Neurosurgery; Baptist Health (A.N.A.), Lyerly Neurosurgery, Jacksonville, FL; Emory University (D.C.H., R.G.N.), Neurology, Atlanta, GA; Riverside Methodist Hospital (R.F.B., W.H., N.V.), Colombia, OH; Saint Louis University (R.C.E.), Neurology, MO; University of Tabuk (T.A.), Neurology, KSA; Baylor Scott & White Health (O.M.), Neurology, Dallas, TX; Greensboro | Cone Health (A.A.), Neurology, Greensboro, NC; Touro Infirmary and New Orleans East Hospital (S.M.-S.), Neurology, LA; UTHealth McGovern Medical School (C.W.S.), Diagnostic and Interventional Radiology, Houston, TX; WellStar Health System (R.G.), Neurology, Marietta, GA; and Memorial Hermann Hospital Texas Medical Center (J.C.G.), Neurology, Houston, TX
| |
Collapse
|
22
|
Kashkoush A, El-Abtah ME, Achey R, Hussain MS, Toth G, Moore NZ, Bain M. Flow Diversion as Destination Treatment of Intracranial Mycotic Aneurysms: A Retrospective Case Series. Oper Neurosurg (Hagerstown) 2023; 24:492-498. [PMID: 36715979 DOI: 10.1227/ons.0000000000000593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2022] [Accepted: 10/21/2022] [Indexed: 01/31/2023] Open
Abstract
BACKGROUND Mycotic aneurysms represent a rare type of intracranial aneurysm. Treatment options usually consist of coiling, clipping, or liquid embolization. Data regarding outcomes after flow diversion of mycotic aneurysms are sparse. OBJECTIVE To present a single-center case series regarding our experience with FD as definitive treatment for ruptured mycotic aneurysms initially treated with coil embolization. METHODS We retrospectively reviewed a prospectively maintained database of all cerebrovascular procedures performed at a single institution between 2017 and 2021 for cases that used FD for the management of intracranial mycotic aneurysms. Prospectively collected data included patient demographics, medical history, rupture status, aneurysm morphology, aneurysm location, and periprocedural complications. The main outcomes included neurological examination and radiographic occlusion rate on cerebral digital subtraction angiography. RESULTS Three patients with 4 ruptured mycotic aneurysms that were initially treated with coil embolization were identified that required retreatment. The aneurysms were located along the middle cerebral artery bifurcation (n = 2), posterior cerebral artery P1/2 junction (n = 1), and basilar artery apex (n = 1), which all demonstrated recurrence after initial coil embolization. Successful retreatment using flow diverting stents was performed in all 3 patients. At the last angiographic follow-up, all aneurysms demonstrated complete occlusion. No patients suffered new periprocedural complications or neurological deficits after FD. CONCLUSION Flow-diverting stents may be an effective treatment option for intracranial mycotic aneurysms that are refractory to previous endovascular coiling. Future studies are warranted to establish the associated long-term safety and clinical efficacy.
Collapse
Affiliation(s)
- Ahmed Kashkoush
- Department of Neurological Surgery, Cleveland Clinic, Cleveland, Ohio, USA
| | - Mohamed E El-Abtah
- Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
| | - Rebecca Achey
- Department of Neurological Surgery, Cleveland Clinic, Cleveland, Ohio, USA
| | | | - Gabor Toth
- Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA
| | - Nina Z Moore
- Department of Neurological Surgery, Cleveland Clinic, Cleveland, Ohio, USA.,Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA
| | - Mark Bain
- Department of Neurological Surgery, Cleveland Clinic, Cleveland, Ohio, USA.,Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA
| |
Collapse
|
23
|
Sarraj A, Pujara DK, Churilov L, Sitton CW, Ng F, Hassan AE, Abraham MG, Blackburn SL, Sharma G, Yassi N, Kleinig T, Shah D, Wu TY, Tekle WG, Budzik RF, Hicks WJ, Vora N, Edgell RC, Haussen D, Ortega-Gutierrez S, Toth G, Maali L, Abdulrazzak MA, Al-Shaibi F, AlMaghrabi T, Yogendrakumar V, Shaker F, Mir O, Arora A, Duncan K, Sundararajan S, Opaskar A, Hu Y, Ray A, Sunshine J, Bambakidis N, Martin-Schild S, Hussain MS, Nogueira R, Furlan A, Sila CA, Grotta JC, Parsons M, Mitchell PJ, Donnan GA, Davis SM, Albers GW, Campbell BCV. Mediation of Successful Reperfusion Effect through Infarct Growth and Cerebral Edema: A Pooled, Patient-Level Analysis of EXTEND-IA Trials and SELECT Prospective Cohort. Ann Neurol 2022; 93:793-804. [PMID: 36571388 DOI: 10.1002/ana.26587] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2022] [Revised: 12/01/2022] [Accepted: 12/16/2022] [Indexed: 12/27/2022]
Abstract
OBJECTIVE Reperfusion therapy is highly beneficial for ischemic stroke. Reduction in both infarct growth and edema are plausible mediators of clinical benefit with reperfusion. We aimed to quantify these mediators and their interrelationship. METHODS In a pooled, patient-level analysis of the EXTEND-IA trials and SELECT study, we used a mediation analysis framework to quantify infarct growth and cerebral edema (midline shift) mediation effect on successful reperfusion (modified Treatment in Cerebral Ischemia ≥ 2b) association with functional outcome (modified Rankin Scale distribution). Furthermore, we evaluated an additional pathway to the original hypothesis, where infarct growth mediated successful reperfusion effect on midline shift. RESULTS A total 542 of 665 (81.5%) eligible patients achieved successful reperfusion. Baseline clinical and imaging characteristics were largely similar between those achieving successful versus unsuccessful reperfusion. Median infarct growth was 12.3ml (interquartile range [IQR] = 1.8-48.4), and median midline shift was 0mm (IQR = 0-2.2). Of 249 (37%) demonstrating a midline shift of ≥1mm, median shift was 2.75mm (IQR = 1.89-4.21). Successful reperfusion was associated with reductions in both predefined mediators, infarct growth (β = -1.19, 95% confidence interval [CI] = -1.51 to -0.88, p < 0.001) and midline shift (adjusted odds ratio = 0.36, 95% CI = 0.23-0.57, p < 0.001). Successful reperfusion association with improved functional outcome (adjusted common odds ratio [acOR] = 2.68, 95% CI = 1.86-3.88, p < 0.001) became insignificant (acOR = 1.39, 95% CI = 0.95-2.04, p = 0.094) when infarct growth and midline shift were added to the regression model. Infarct growth and midline shift explained 45% and 34% of successful reperfusion effect, respectively. Analysis considering an alternative hypothesis demonstrated consistent results. INTERPRETATION In this mediation analysis from a pooled, patient-level cohort, a significant proportion (~80%) of successful reperfusion effect on functional outcome was mediated through reduction in infarct growth and cerebral edema. Further studies are required to confirm our findings, detect additional mediators to explain successful reperfusion residual effect, and identify novel therapeutic targets to further enhance reperfusion benefits. ANN NEUROL 2023.
Collapse
Affiliation(s)
- Amrou Sarraj
- Department of Neurology, Case Western Reserve University, Cleveland, OH, USA.,Department of Neurology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
| | - Deep K Pujara
- Department of Neurology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
| | - Leonid Churilov
- Department of Neurology, Royal Melbourne Hospitals, University of Melbourne, Parkville, Victoria, Australia
| | - Clark W Sitton
- Department of Diagnostic and Interventional Radiology, UTHealth McGovern Medical School, Houston, TX, USA
| | - Felix Ng
- Department of Neurology, Royal Melbourne Hospitals, University of Melbourne, Parkville, Victoria, Australia
| | - Ameer E Hassan
- University of Texas Rio Grande Valley-Valley Baptist Medical Center, Harlingen, TX, USA
| | - Michael G Abraham
- Department of Neurology and Radiology, University of Kansas Medical Center, Kansas City, KS, USA
| | - Spiros L Blackburn
- Department of Neurosurgery, UTHealth McGovern Medical School, Houston, TX, USA
| | - Gagan Sharma
- Department of Neurology, Royal Melbourne Hospitals, University of Melbourne, Parkville, Victoria, Australia
| | - Nawaf Yassi
- Department of Neurology, Royal Melbourne Hospitals, University of Melbourne, Parkville, Victoria, Australia.,Walter and Eliza Hall Institute of Medical Research, Population Health and Immunity, Parkville, Victoria, Australia
| | - Timothy Kleinig
- Department of Neurology, Royal Adelaide Hospital, Adelaide, South Australia, Australia
| | - Darshan Shah
- Department of Neurology, Gold Coast University Hospital, Southport, Queensland, Australia
| | - Teddy Y Wu
- Department of Neurology, Christchurch Hospital, Christchurch, New Zealand
| | - Wondwossen G Tekle
- University of Texas Rio Grande Valley-Valley Baptist Medical Center, Harlingen, TX, USA
| | | | | | - Nirav Vora
- Riverside Methodist Hospital, Colombia, OH, USA
| | - Randall C Edgell
- Department of Neurology, Saint Louis University, Saint Louis, MO, USA
| | - Diogo Haussen
- Department of Neurology, Emory University, Atlanta, GA, USA
| | | | - Gabor Toth
- Department of Neurology, Cleveland Clinic, Cleveland, OH, USA
| | - Laith Maali
- Department of Neurology and Radiology, University of Kansas Medical Center, Kansas City, KS, USA
| | | | - Faisal Al-Shaibi
- Department of Neurology, Case Western Reserve University, Cleveland, OH, USA
| | - Tareq AlMaghrabi
- Department of Neurology, University of Tabuk, Tabuk, Kingdom of Saudi Arabia
| | - Vignan Yogendrakumar
- Department of Neurology, Royal Melbourne Hospitals, University of Melbourne, Parkville, Victoria, Australia
| | - Faris Shaker
- Department of Neurosurgery, UTHealth McGovern Medical School, Houston, TX, USA
| | - Osman Mir
- Department of Neurology, Baylor Scott & White Health, Dallas, TX, USA
| | - Ashish Arora
- Department of Neurology, Greensboro
- Cone Health, Greensboro, NC, USA
| | - Kelsey Duncan
- Department of Neurosurgery, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
| | - Sophia Sundararajan
- Department of Neurology, Case Western Reserve University, Cleveland, OH, USA.,Department of Neurology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
| | - Amanda Opaskar
- Department of Neurosurgery, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
| | - Yin Hu
- Department of Neurosurgery, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
| | - Abhishek Ray
- Department of Neurosurgery, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
| | - Jeffrey Sunshine
- Department of Neurosurgery, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
| | - Nicholas Bambakidis
- Department of Neurosurgery, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
| | - Sheryl Martin-Schild
- Department of Neurology, Touro Infirmary and New Orleans East Hospital, New Orleans, LA, USA
| | | | - Raul Nogueira
- Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
| | - Anthony Furlan
- Department of Neurology, Case Western Reserve University, Cleveland, OH, USA.,Department of Neurology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
| | - Cathy A Sila
- Department of Neurology, Case Western Reserve University, Cleveland, OH, USA.,Department of Neurology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
| | - James C Grotta
- Department of Neurology, Memorial Hermann Hospital Texas Medical Center, Houston, TX, USA
| | - Mark Parsons
- Department of Neurology, University of Newcastle, Newcastle, New South Wales, Australia
| | - Peter J Mitchell
- Department of Radiology, Royal Melbourne Hospital-University of Melbourne, Parkville, Victoria, Australia
| | - Geoffrey A Donnan
- Department of Neurology, Royal Melbourne Hospitals, University of Melbourne, Parkville, Victoria, Australia
| | - Stephen M Davis
- Department of Neurology, Royal Melbourne Hospitals, University of Melbourne, Parkville, Victoria, Australia
| | | | - Bruce C V Campbell
- Department of Neurology, Royal Melbourne Hospitals, University of Melbourne, Parkville, Victoria, Australia
| | | |
Collapse
|
24
|
Figueiredo CA, Düsedau HP, Steffen J, Ehrentraut S, Dunay MP, Toth G, Reglödi D, Heimesaat MM, Dunay IR. The neuropeptide PACAP alleviates T. gondii infection-induced neuroinflammation and neuronal impairment. J Neuroinflammation 2022; 19:274. [PMCID: PMC9675261 DOI: 10.1186/s12974-022-02639-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2022] [Accepted: 10/23/2022] [Indexed: 11/21/2022] Open
Abstract
Background Cerebral infection with the protozoan Toxoplasma gondii (T. gondii) is responsible for inflammation of the central nervous system (CNS) contributing to subtle neuronal alterations. Albeit essential for brain parasite control, continuous microglia activation and recruitment of peripheral immune cells entail distinct neuronal impairment upon infection-induced neuroinflammation. PACAP is an endogenous neuropeptide known to inhibit inflammation and promote neuronal survival. Since PACAP is actively transported into the CNS, we aimed to assess the impact of PACAP on the T. gondii-induced neuroinflammation and subsequent effects on neuronal homeostasis. Methods Exogenous PACAP was administered intraperitoneally in the chronic stage of T. gondii infection, and brains were isolated for histopathological analysis and determination of pathogen levels. Immune cells from the brain, blood, and spleen were analyzed by flow cytometry, and the further production of inflammatory mediators was investigated by intracellular protein staining as well as expression levels by RT-qPCR. Neuronal and synaptic alterations were assessed on the transcriptional and protein level, focusing on neurotrophins, neurotrophin-receptors and signature synaptic markers. Results Here, we reveal that PACAP administration reduced the inflammatory foci and the number of apoptotic cells in the brain parenchyma and restrained the activation of microglia and recruitment of monocytes. The neuropeptide reduced the expression of inflammatory mediators such as IFN-γ, IL-6, iNOS, and IL-1β. Moreover, PACAP diminished IFN-γ production by recruited CD4+ T cells in the CNS. Importantly, PACAP promoted neuronal health via increased expression of the neurotrophin BDNF and reduction of p75NTR, a receptor related to neuronal cell death. In addition, PACAP administration was associated with increased expression of transporters involved in glutamatergic and GABAergic signaling that are particularly affected during cerebral toxoplasmosis. Conclusions Together, our findings unravel the beneficial effects of exogenous PACAP treatment upon infection-induced neuroinflammation, highlighting the potential implication of neuropeptides to promote neuronal survival and minimize synaptic prejudice. Supplementary Information The online version contains supplementary material available at 10.1186/s12974-022-02639-z.
Collapse
Affiliation(s)
- Caio Andreeta Figueiredo
- grid.5807.a0000 0001 1018 4307Institute of Inflammation and Neurodegeneration, Health Campus Immunology, Infectiology and Inflammation (GC-I3), Otto-Von-Guericke University, Magdeburg, Germany
| | - Henning Peter Düsedau
- grid.5807.a0000 0001 1018 4307Institute of Inflammation and Neurodegeneration, Health Campus Immunology, Infectiology and Inflammation (GC-I3), Otto-Von-Guericke University, Magdeburg, Germany
| | - Johannes Steffen
- grid.5807.a0000 0001 1018 4307Institute of Inflammation and Neurodegeneration, Health Campus Immunology, Infectiology and Inflammation (GC-I3), Otto-Von-Guericke University, Magdeburg, Germany
| | - Stefanie Ehrentraut
- grid.5807.a0000 0001 1018 4307Institute of Inflammation and Neurodegeneration, Health Campus Immunology, Infectiology and Inflammation (GC-I3), Otto-Von-Guericke University, Magdeburg, Germany
| | - Miklos P. Dunay
- grid.483037.b0000 0001 2226 5083Department and Clinic of Surgery and Ophthalmology, University of Veterinary Medicine, Budapest, Hungary
| | - Gabor Toth
- grid.9008.10000 0001 1016 9625Department of Medical Chemistry, University of Szeged, Budapest, Hungary
| | - Dora Reglödi
- grid.9679.10000 0001 0663 9479Department of Anatomy, MTA-PTE PACAP Research Team and Szentagothai Research Center, University of Pecs Medical School, Pecs, Hungary
| | - Markus M. Heimesaat
- grid.6363.00000 0001 2218 4662Institute of Microbiology, Infectious Diseases and Immunology, Charité - University Medicine Berlin, Berlin, Germany
| | - Ildiko Rita Dunay
- grid.5807.a0000 0001 1018 4307Institute of Inflammation and Neurodegeneration, Health Campus Immunology, Infectiology and Inflammation (GC-I3), Otto-Von-Guericke University, Magdeburg, Germany ,grid.418723.b0000 0001 2109 6265Center for Behavioral Brain Sciences – CBBS, Magdeburg, Germany
| |
Collapse
|
25
|
Achim A, Kakonyi K, Nagy F, Jambrik Z, Varga A, Nemes A, Sk Chan J, Toth G, Ruzsa Z. Radial artery calcification in predicting coronary calcification and atherosclerosis burden. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Atherosclerosis is a systemic arterial disease with heterogeneous involvement in all vascular beds, however studies examining the relationship between coronary and radial artery calcification are lacking.
The purpose of this study was to assess the relationship between the two sites and the prognostic value of radial artery calcification (RC) for coronary artery disease.
Methods and results
This is a single-center, retrospective cross-sectional study based on doppler ultrasound of radial artery (RUS) and coronary artery angiography (CAG). We included a total of 202 patients undergoing RUS during distal radial access and CAG at the same procedure, between December 2020 and May 2021, from which 103 were found having RC during RUS (RC-group) and 99 without (NRC-group). Coronary calcifications were evaluated either by angiography examination (moderate and severe), positive CT (>100 Agatson units) or intracoronary imaging (IVUS, OCT). A significant correlation was observed between radial calcification and coronary calcification variables (67.3%, vs 32.7% – p=0.001). The correlation between risk factors such as age, smoking, chronic kidney disease and diabetes mellitus was higher while sex did not play a role. The need of PCI and/or CABG was higher in the RC-group (60% vs 44%, p=0.02). RC therefore predicts the extent and severity of coronary artery disease.
Conclusion
RC may be frequently associated with calcific coronary plaques. These findings highlight the potential beneficial examination of radial arteries whenever CAD is suspected.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- A Achim
- University of Medicine and Pharmacy of Cluj Napoca, Institutul Inimii , Cluj Napoca , Romania
| | - K Kakonyi
- University of Szeged, Invasive Cardiology , Szeged , Hungary
| | - F Nagy
- University of Szeged, Invasive Cardiology , Szeged , Hungary
| | - Z Jambrik
- University of Szeged, Invasive Cardiology , Szeged , Hungary
| | - A Varga
- University of Szeged, Invasive Cardiology , Szeged , Hungary
| | - A Nemes
- University of Szeged, Invasive Cardiology , Szeged , Hungary
| | - J Sk Chan
- The Chinese University of Hong Kong , Hong Kong , Hong Kong
| | - G Toth
- Medical University of Graz , Graz , Austria
| | - Z Ruzsa
- University of Szeged, Invasive Cardiology , Szeged , Hungary
| |
Collapse
|
26
|
Farag E, Argalious M, Toth G. Stroke thrombectomy perioperative anesthetic and hemodynamic management. J Neurointerv Surg 2022; 15:483-487. [PMID: 35697516 DOI: 10.1136/neurintsurg-2021-018300] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2022] [Accepted: 05/21/2022] [Indexed: 11/04/2022]
Abstract
There is an ongoing debate about the optimal anesthetic and hemodynamic management of acute stoke patients with large vessel occlusion undergoing endovascular mechanical thrombectomy. Several prospective and retrospective analyses, and randomized controlled trials, attempted to address the challenges of using different anesthetic modalities in acute stroke patients requiring mechanical thrombectomy. We review the advantages and disadvantages of monitored anesthesia care, local anesthesia, conscious sedation, and general anesthesia, along with the relevance of hemodynamic management and perioperative oxygenation status in these complex patients.
Collapse
Affiliation(s)
- Ehab Farag
- Department of General Anesthesia, Anesthesiology and Pain Management Institute, Cleveland Clinic, Cleveland, Ohio, USA.,Department of Outcomes Research, Anesthesiology and Pain Management Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Maged Argalious
- Department of General Anesthesia, Anesthesiology and Pain Management Institute, Cleveland Clinic, Cleveland, Ohio, USA
| | - Gabor Toth
- Cerebrovascular Center, Neurologic Institute, Cleveland Clinic, Cleveland, Ohio, USA
| |
Collapse
|
27
|
Achey RL, Winkelman R, Sheikhi L, Davison M, Toth G, Moore N, Bain M. Use of Surpass Streamline Flow Diverter for the Endovascular Treatment of Craniocervical Aneurysms: a Single-Institution Experience. World Neurosurg 2022; 162:e281-e287. [PMID: 35276392 DOI: 10.1016/j.wneu.2022.03.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Revised: 02/28/2022] [Accepted: 03/01/2022] [Indexed: 11/25/2022]
Abstract
INTRODUCTION Flow diversion has revolutionized endovascular treatment for cerebral aneurysms. Surpass Streamline flow-diverter (SSFD) has shown promise for expanding flow diversion device options for aneurysm treatment. The SSFD differs from earlier stents by maintaining high porosity with increased pore density to ensure appropriate flow disruption. Given the delivery system's increased dimension options, and potential greater flow diverting properties, the SSFD is poised to extend the anatomic/pathologic reaches of flow diversion therapy. METHODS Data pertaining to SSFD-treated aneurysms were gathered retrospectively from 2019 to 2020. Collected information included aneurysm location, size, symptoms, complications, and occlusions rates at follow-up. Size was categorized as small (<10 mm), large (10-25 mm), and giant (>25 mm) according to SCENT trial criteria. Aneurysm occlusion on follow-up imaging was characterized by SMART grading with adequate occlusion defined as grades 3 and 4. Imaging was performed at time of treatment, six-month, and one-year follow-up. RESULTS 42 SSFD-treated aneurysms were treated throughout the cerebrovascular system; 3 cervical, 4 posterior, and 35 intracranial anterior circulation. Complete occlusion rates at six months and one year were 48% and 57% with adequate occlusion achieved in 89.6% and 85.7% respectively. Rates of complete occlusion were higher for small aneurysms (69%) compared to large aneurysms (38%). CONCLUSIONS Our data suggests comparable complete occlusion rates compared to the SCENT trial (66.1% vs 57% in our center) and adequate occlusion rates. Similar occlusion rates to prior studies despite broadened inclusion criteria/diversity of aneurysms treated demonstrates favorable generalizability of flow-diverting technology to a wide array of aneurysmal pathology.
Collapse
Affiliation(s)
- R L Achey
- Department of Neurosurgery, Cleveland Clinic Foundation, Cleveland OH
| | - R Winkelman
- Department of Neurosurgery, Cleveland Clinic Foundation, Cleveland OH
| | - L Sheikhi
- University of Kentucky, Kentucky Neuroscience Institute, Lexington KY
| | - M Davison
- Department of Neurosurgery, Cleveland Clinic Foundation, Cleveland OH
| | - G Toth
- Department of Neurosurgery, Cleveland Clinic Foundation, Cleveland OH; Cerebrovascular Center, Cleveland Clinic Foundation, Cleveland OH
| | - N Moore
- Department of Neurosurgery, Cleveland Clinic Foundation, Cleveland OH; Cerebrovascular Center, Cleveland Clinic Foundation, Cleveland OH
| | - M Bain
- Department of Neurosurgery, Cleveland Clinic Foundation, Cleveland OH; Cerebrovascular Center, Cleveland Clinic Foundation, Cleveland OH.
| |
Collapse
|
28
|
Toth G, Görföl T, Boldogh S, Lanszki Z, Balázs-Nagy Á, Jakab F, Kemenesi G. Concept of Resampling: Protocol for the Field-based Detection and Characterization of the European Filovirus (Lloviu cuevavirus). Int J Infect Dis 2022. [DOI: 10.1016/j.ijid.2021.12.161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
29
|
Hanel RA, Yoon N, Sauvageau E, Aghaebrahim A, Lin E, Jadhav AP, Jovin TG, Khaldi A, Gupta RG, Johnson A, Frei D, Loy D, Malek A, Toth G, Siddiqui A, Reavey-Cantwell J, Thomas A, Hetts SW, Jankowitz BT, Zaidat OO. Neuroform Atlas Stent for Treatment of Middle Cerebral Artery Aneurysms: 1-Year Outcomes From Neuroform Atlas Stent Pivotal Trial. Neurosurgery 2021. [DOI: 10.1093/neuros/nyab090_s136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Hussain Y, Wijns W, Xu B, Kelbæk H, Knaapen P, Zheng M, Slagboom T, Johnson T, Smits P, Arkenbout K, Holmvang L, Janssens L, Ochala A, Brugaletta S, Schmitz T, Anderson RA, Rittger H, Berti S, Barbato E, Toth G, Maillard L, Valina C, Buszman P, Thiele H, Schachinger V, Baumbach A, Lansky A. TCT-489 Three-Year Outcomes of Patients Treated With the Firehawk Stent Versus XIENCE Stent on the Basis of Diabetes Status: Subgroup Analysis of the TARGET All Comers Trial. J Am Coll Cardiol 2021. [DOI: 10.1016/j.jacc.2021.09.1342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
31
|
Zweiker D, Sieghartsleitner R, Toth G, Stix G, Vock P, Schratter A, Fiedler L, Aichinger J, Steinwender C, Binder R, Barbieri F, Ablasser K, Verheyen N, Zirlik A, Scherr D. Low haemoglobin is associated with increased risk of complications in left atrial appendage closure patients. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Left atrial appendage closure is associated with a relevant procedural complication rate. Baseline risk factors, such as pre-procedural lab results, may identify patients that develop acute complications.
Methods
We performed a retrospective analysis of the impact of baseline characteristics and preprocedural lab results on the acute procedural outcome in patients undergoing left atrial appendage closure from the Austrian Left Atrial Appendage Closure Registry between 2010 and 2019. The endpoint for procedural complications was defined as death, stroke, major bleeding, necessity for intensive care, other complications requiring invasive interventions or failure to implant the device. We also evaluated a modified endpoint with the exclusion of bleeding events. Logistic regression was performed using stepwise approach (backward method with p_out = 0.1) and forced inclusion of age, left-ventricular function and kidney function.
Results
A total of 320 consecutive patients from 9 centres with a median age of 75 years (36.6% female) were included. Seventy-eight percent had a history of bleeding and 35% had a history of stroke. Median CHA2DS2-VASc score was 5 (interquartile range, 3–5) and median HAS-BLED score was 3 (2–4). Procedural complications occurred in 15.3% of cases. Low haemoglobin and low activated partial thromboplastin time were associated with an increased complication rate. Other significant baseline factors were liver disease, absence of intracranial haemorrhage and severe aortic stenosis. In multivariate analysis, low haemoglobin remained a significant predictor, even after adjustment for age, left-ventricular function and kidney function (Table). In the modified procedural complication endpoint excluding major bleeding events (14.1%), low haemoglobin remained a significant predictor (haemoglobin 11.9±2.0 vs. 12.8±2.0 g/dL in patients with vs. without modified endpoint, p=0.013). A baseline haemoglobin lower than 12 g/dL was present in 39.4% and it increased relative risk of procedural complications by 89% (21.4 vs. 11.3% in patients with reduced vs. normal haemoglobin), and risk of complications without bleeding by 92% (19.8 vs. 10.3%).
Conclusion
Low baseline haemoglobin is independently associated with a higher complication rate after left appendage closure compared to patients with normal haemoglobin levels, even in a modified endpoint excluding bleeding and requirement for transfusion.
Funding Acknowledgement
Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): Boston Scientific - unrestricted grant Table 1
Collapse
Affiliation(s)
- D Zweiker
- Medical University of Graz, Division of Cardiology, Graz, Austria
| | | | - G Toth
- Medical University of Graz, Division of Cardiology, Graz, Austria
| | - G Stix
- Medical University of Vienna, Division of Cardiology, Vienna, Austria
| | - P Vock
- University Hospital St. Polten, Department of Internal Medicine 3, St. Polten, Austria
| | - A Schratter
- Floridsdorf Clinic, Department of Cardiology, Vienna, Austria
| | - L Fiedler
- LK Wiener Neustadt Abteilung fuer Kardiologie und Nephrologie, Wiener Neustadt, Austria
| | - J Aichinger
- Ordensklinikum Linz Elisabethinen, Department of Internal Medicine 2, Linz, Austria
| | - C Steinwender
- Kepler University Hospital, Division of Cardiology, Linz, Austria
| | - R.K Binder
- Klinikum Wels-Grieskirchen, Department of Internal Medicine 2, Wels, Austria
| | - F Barbieri
- Medical University of Innsbruck, Department of Internal Medicine 3, Innsbruck, Austria
| | - K Ablasser
- Medical University of Graz, Division of Cardiology, Graz, Austria
| | - N Verheyen
- Medical University of Graz, Division of Cardiology, Graz, Austria
| | - A Zirlik
- Medical University of Graz, Division of Cardiology, Graz, Austria
| | - D Scherr
- Medical University of Graz, Division of Cardiology, Graz, Austria
| | | |
Collapse
|
32
|
Farag E, Liang C, Mascha EJ, Toth G, Argalious M, Manlapaz M, Gomes J, Ebrahim Z, Hussain MS. Oxygen Saturation and Postoperative Mortality in Patients With Acute Ischemic Stroke Treated by Endovascular Thrombectomy. Anesth Analg 2021; 134:369-379. [PMID: 34609988 DOI: 10.1213/ane.0000000000005763] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
BACKGROUND Monitored anesthesia care (MAC) and general anesthesia (GA) with endotracheal intubation are the 2 most used techniques for patients with acute ischemic stroke (AIS) undergoing endovascular thrombectomy. We aimed to test the hypothesis that increased arterial oxygen concentration during reperfusion period is a mechanism underlying the association between use of GA (versus MAC) and increased risk of in-hospital mortality. METHODS In this retrospective cohort study, data were collected at the Cleveland Clinic between 2013 and 2018. To assess the potential mediation effect of time-weighted average oxygen saturation (Spo2) in first postoperative 48 hours between the association between GA versus MAC and in-hospital mortality, we assessed the association between anesthesia type and post-operative Spo2 tertiles (exposure-mediator relationship) through a cumulative logistic regression model and assessed the association between Spo2 and in-hospital mortality (mediator-outcome relationship) using logistic regression models. Confounding factors were adjusted for using propensity score methods. Both significant exposure-mediator and significant mediator-outcome relationships are needed to suggest potential mediation effect. RESULTS Among 358 patients included in the study, 104 (29%) patients received GA and 254 (71%) received MAC, with respective hospital mortality rate of 19% and 5% (unadjusted P value <.001). GA patients were 1.6 (1.2, 2.1) (P < .001) times more likely to have a higher Spo2 tertile as compared to MAC patients. Patients with higher Spo2 tertile had 3.8 (2.1, 6.9) times higher odds of mortality than patients with middle Spo2 tertile, while patients in the lower Spo2 tertile did not have significant higher odds compared to the middle tertile odds ratio (OR) (1.8 [0.9, 3.4]; overall P < .001). The significant exposure-mediator and mediator-outcome relationships suggest that Spo2 may be a mediator of the relationship between anesthetic method and mortality. However, the estimated direct effect of GA versus MAC on mortality (ie, after adjusting for Spo2; OR [95% confidence interval {CI}] of 2.1 [0.9-4.9]) was close to the estimated association ignoring Spo2 (OR [95% CI] of 2.2 [1.0-5.1]), neither statistically significant, suggesting that Spo2 had at most a modest mediator role. CONCLUSIONS GA was associated with a higher Spo2 compared to MAC among those treated by endovascular thrombectomy for AIS. Spo2 values that were higher than the middle tertile were associated with higher odds of mortality. However, GA was not significantly associated with higher odds of death. Spo2 at most constituted a modest mediator role in explaining the relationship between GA versus MAC and mortality.
Collapse
Affiliation(s)
- Ehab Farag
- From the Department of General Anesthesia.,Department of Outcomes Research, Anesthesiology & Pain Management Institute
| | - Chen Liang
- Department of Outcomes Research, Anesthesiology & Pain Management Institute.,Department of Quantitative Health Sciences, Lerner Research Institute
| | - Edward J Mascha
- Department of Outcomes Research, Anesthesiology & Pain Management Institute.,Department of Quantitative Health Sciences, Lerner Research Institute
| | - Gabor Toth
- Department of Neurointerventional Radiology
| | | | | | - Joao Gomes
- Department of Neurology, Neurological Institute, The Cleveland Clinic, Cleveland, Ohio
| | | | | |
Collapse
|
33
|
Affiliation(s)
- Gabor Toth
- Cerebrovascular Center, Cleveland Clinic, Cleveland, Ohio, USA
| | - Luis Savastano
- Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA
| | - Bharathi D Jagadeesan
- Department of Radiology, Neurosurgery and Neurology, University of Minnesota, Minneapolis, Minnesota, USA
| |
Collapse
|
34
|
Szabo E, Patko E, Vaczy A, Molitor D, Csutak A, Toth G, Reglodi D, Atlasz T. Retinoprotective Effects of PACAP Eye Drops in Microbead-Induced Glaucoma Model in Rats. Int J Mol Sci 2021; 22:8825. [PMID: 34445531 PMCID: PMC8396165 DOI: 10.3390/ijms22168825] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Revised: 08/09/2021] [Accepted: 08/13/2021] [Indexed: 01/29/2023] Open
Abstract
Glaucoma is associated with increased intraocular pressure (IOP), causing the apoptosis of retinal ganglion cells (RGCs) and the loss of their axons leading to blindness. Pituitary adenylate cyclase activating polypeptide (PACAP) is neuroprotective in several neural injuries, including retinopathies. The aim of this study was to investigate the effects of PACAP1-38 eye drops in a model of glaucoma. IOP was elevated bilaterally by injections of microbeads to block the aqueous humor outflow. The control groups received the same volume of saline. Animals were treated with PACAP1-38 (1 µg/drop, 3 × 1 drop/day) or vehicle for 4 weeks starting one day after the injections. Retinal morphology by histology and optical coherence tomography, function by electroretinography, and IOP changes were analyzed. Animals were sacrificed 8 weeks after the injections. Microbeads injections induced a significant increase in the IOP, while PACAP1-38 treatment lowered it to normal levels (~10 mmHg). Significant retinal degeneration and functional impairment were observed in the microbead-injected group without PACAP1-38 treatment. In the microbeads + PACAP1-38 group, the retinal morphology and functionality were close to the normal values. In summary, our results show that PACAP1-38, given in form of eye drops, is neuroprotective in glaucoma, providing the basis for potential future therapeutic administration.
Collapse
Affiliation(s)
- Edina Szabo
- Department of Anatomy, MTA-PTE PACAP Research Team, University of Pecs Medical School, 7624 Pecs, Hungary; (E.S.); (E.P.); (A.V.); (D.M.); (D.R.)
| | - Evelin Patko
- Department of Anatomy, MTA-PTE PACAP Research Team, University of Pecs Medical School, 7624 Pecs, Hungary; (E.S.); (E.P.); (A.V.); (D.M.); (D.R.)
| | - Alexandra Vaczy
- Department of Anatomy, MTA-PTE PACAP Research Team, University of Pecs Medical School, 7624 Pecs, Hungary; (E.S.); (E.P.); (A.V.); (D.M.); (D.R.)
| | - Dorottya Molitor
- Department of Anatomy, MTA-PTE PACAP Research Team, University of Pecs Medical School, 7624 Pecs, Hungary; (E.S.); (E.P.); (A.V.); (D.M.); (D.R.)
| | - Adrienne Csutak
- Department of Ophthalmology, Clinical Centre, University of Pecs Medical School, 7632 Pecs, Hungary;
| | - Gabor Toth
- Department of Medical Chemistry, Faculty of Medicine, University of Szeged, 6720 Szeged, Hungary;
| | - Dora Reglodi
- Department of Anatomy, MTA-PTE PACAP Research Team, University of Pecs Medical School, 7624 Pecs, Hungary; (E.S.); (E.P.); (A.V.); (D.M.); (D.R.)
- Szentagothai Research Center, University of Pecs, 7624 Pecs, Hungary
| | - Tamas Atlasz
- Department of Anatomy, MTA-PTE PACAP Research Team, University of Pecs Medical School, 7624 Pecs, Hungary; (E.S.); (E.P.); (A.V.); (D.M.); (D.R.)
- Szentagothai Research Center, University of Pecs, 7624 Pecs, Hungary
- Department of Sportbiology, University of Pecs, 7624 Pecs, Hungary
| |
Collapse
|
35
|
Van Belle E, Teles RC, Pyxaras SA, Kalpak O, Johnson TW, Barbash I, De Luca G, Kostov J, Parma R, Vincent F, Brugaletta S, Debry N, Toth G, Ghazzal Z, Deharo P, Milasinovic D, Kaspar K, Saia F, Mauri Ferre J, Kammler J, Muir D, O'Connor S, Mehilli J, Thiele H, Weilenmann D, Witt N, Joshi F, Kharbanda RKK, Piroth Z, Wojakowski W, Geppert A, Di Gioia G, Pires-Morais G, Petronio A, Estévez-Loureiro R, Ruzsa Z, Kefer J, Kunadian V, Van Mieghem N, Windecker S, Baumbach A, Haude M, Dudek D. EAPCI Core Curriculum for Percutaneous Cardiovascular Interventions (2020): Committee for Education and Training European Association of Percutaneous Cardiovascular Interventions (EAPCI). A branch of the European Society of Cardiology. EUROINTERVENTION 2021; 17:23-31. [PMID: 32624457 PMCID: PMC9725044 DOI: 10.4244/eij-d-18-00448] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
The proposed 2020 Core Curriculum for Percutaneous Cardiovascular Interventions aims to provide an updated European consensus that defines the level of experience and knowledge in the field of percutaneous cardiovascular intervention (PCI). It promotes homogenous education and training programmes among countries, and is the cornerstone of the new EAPCI certification, designed to support the recognition of competencies at the European level and the free movement of certified specialists in the European Community. It is based on a thorough review of the ESC guidelines and of the EAPCI textbook on percutaneous interventional cardiovascular medicine. The structure of the current core curriculum evolved from previous EAPCI core curricula and from the "2013 core curriculum of the general cardiologist" to follow the current ESC recommendations for core curricula. In most subject areas, there was a wide - if not unanimous - consensus among the task force members on the training required for the interventional cardiologist of the future. The document recommends that acquisition of competence in interventional cardiology requires at least two years of postgraduate training, in addition to four years devoted to cardiology. The first part of the curriculum covers general aspects of training and is followed by a comprehensive description of the specific components in 54 chapters. Each of the chapters includes statements of the objectives, and is further subdivided into the required knowledge, skills, behaviours, and attitudes.
Collapse
Affiliation(s)
- Eric Van Belle
- Institut Coeur Poumon (Heart and Lung Institute), Bd du Pr Leclercq, CHU Lille, 59000 Lille, France
| | - Rui Campante Teles
- Hospital de Santa Cruz CHLO, Carnaxide, Portugal; CEDOC, Nova Medical School, Lisboa, Portugal
| | | | | | | | - Israel Barbash
- Leviev Heart Center, Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel
| | - Giuseppe De Luca
- AOU Maggiore della Carità, Eastern Piedmont University, Novara, Italy
| | | | - Radoslaw Parma
- Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
| | - Flavien Vincent
- CHRU Lille, Institut Coeur-Poumon, Department of Cardiology, Lille, France
| | - Salvatore Brugaletta
- Hospital Clinic, Cardiovascular Clinic Institute, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Nicolas Debry
- CHRU Lille, Institut Coeur-Poumon, Department of Cardiology, Lille, France
| | - Gabor Toth
- University Heart Center Graz, Medical University Graz, Graz, Austria
| | - Ziyad Ghazzal
- American University of Beirut Faculty of Medicine and Medical Center, Lebanon
| | | | - Dejan Milasinovic
- Clinical Center of Serbia, Department of Cardiology, Belgrade, Serbia
| | | | - Francesco Saia
- Cardio-Thoraco-Vascular Department University Hospital of Bologna, Policlinico S. Orsola - Malpighi (Pav. 23), Bologna, Italy
| | | | - Jürgen Kammler
- Med Campus III., Kepler University Hospital Linz, Faculty of Medicine, Johannes Kepler University Linz, Linz, Austria
| | - Douglas Muir
- The James Cook University Hospital, Middlesbrough, United Kingdom
| | | | - Julinda Mehilli
- Med. Klinik und Poliklinik I, Klinikum der Universitaet, Ludwig-Maximilian University, Munich Heart Alliance at DZHK, Munich, Germany
| | - Holger Thiele
- Heart Center Leipzig at University of Leipzig, Department of Internal Medicine/Cardiology and Leipzig Heart Institute, Leipzig, Germany
| | - Daniel Weilenmann
- Department of Cardiology, Kantonsspital St. Gallen, Gallen, Switzerland
| | - Nils Witt
- Department of clinical science and education, Karolinska Institute, Division of cardiology Södersjukhuset, Stockholm, Sweden
| | - Francis Joshi
- Department of Cardiology, Rigshospitalet, Copenhagen, Denmark
| | | | - Zsolt Piroth
- Hungarian Institute of Cardiology, Haller street, Budapest, Hungary
| | - Wojciech Wojakowski
- Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
| | | | | | - Gustavo Pires-Morais
- Cardiovascular Intervention Unit, Department of Cardiology, Centro Hospitalar de Vila Nova de Gaia, Vila Nova de Gaia, Portugal
| | - Anna Petronio
- Cardiothoracic and Vascular Dpt. AOUP,University of Pisa, Italy
| | | | - Zoltan Ruzsa
- Semmelweis University, Heart and Vascular Center, Budapest, Hungary
| | - Joelle Kefer
- Cliniques universitaires Saint-Luc, Bruxelles, Belgium
| | - Vijay Kunadian
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University and Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, United Kingdom
| | - Nicolas Van Mieghem
- Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands
| | - Stephan Windecker
- Department of Cardiology, Swiss Cardiovascular Center, University Hospital Bern, Bern, Switzerland
| | - Andreas Baumbach
- Queen Mary University of London, Barts Heart Centre, London, United Kingdom
| | - Michael Haude
- Med. Klinik I, Städtische Kliniken Neuss, Lukaskrankenhaus GmbH, Neuss, Germany
| | - Dariusz Dudek
- Jagiellonian University Medical College in Poland, Krakow, Poland
| |
Collapse
|
36
|
Hanel RA, Yoon N, Sauvageau E, Aghaebrahim A, Lin E, Jadhav AP, Jovin TG, Khaldi A, Gupta RG, Johnson A, Frei D, Loy D, Malek A, Toth G, Siddiqui A, Reavey-Cantwell J, Thomas A, Hetts SW, Jankowitz BT, Zaidat OO. Neuroform Atlas Stent for Treatment of Middle Cerebral Artery Aneurysms: 1-Year Outcomes From Neuroform Atlas Stent Pivotal Trial. Neurosurgery 2021; 89:102-108. [PMID: 33826707 DOI: 10.1093/neuros/nyab090] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2020] [Accepted: 01/21/2021] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Heterogeneous effect of endovascular aneurysm therapy has been observed across different anatomic locations. There is a paucity of data for stent-assisted coiling of middle cerebral artery (MCA) aneurysms. OBJECTIVE To present the results of the MCA aneurysm group from the Neuroform Atlas (Stryker Neurovascular) investigational device exemption (IDE) trial. METHODS The Atlas IDE trial is a prospective, multicenter, single-arm, open-label study of wide-neck aneurysms (neck ≥ 4 mm or dome-to-neck ratio < 2) in the anterior circulation treated with the Neuroform Atlas Stent and approved coils. Follow-up was obtained immediately postprocedure and 2, 6, and 12 mo postoperatively. We herein describe safety and efficacy outcomes, and functional independence of the subjects with aneurysms from all segments of MCA. RESULTS A total of 35 patients were included (27 MCA bifurcation, 5 M1, 3 M2). The mean aneurysm size was 6.0 ± 1.8 mm, and the mean neck was 4.4 ± 1.2 mm. Technical procedural success was achieved in all patients. A total of 26 patients had follow-up digital subtraction angiography available at 12 mo, with 80.8% (21/26) having complete aneurysm occlusion. Twelve-month safety data were collected for 91.4% (32/35), 8.5% (3/35) had primary safety endpoint, all 3 major ischemic strokes. Mortality occurred in 2 patients beyond 30 d unrelated to procedure (1 gallbladder cancer and 1 fentanyl intoxication). At 1 yr, modified Rankin Score was 0 to 2 in 84.4% (27/32), 3 in 9.4%, and 3 patients were missing. Approximately 5.7% (2/35) of patients were retreated at 12 mo. CONCLUSION Stent-assisted coiling with the Neuroform Atlas Stent is a viable alternative to clipping for selected MCA aneurysms. Complete aneurysm occlusion rates have improved compared to historical data. Proper case selection can lead to acceptable endovascular results.
Collapse
Affiliation(s)
| | - Nam Yoon
- Lyerly Neurosurgery, Jacksonville, Florida, USA
| | | | | | - Eugene Lin
- Neuroscience Department, Bon Secours Mercy Health St. Vincent Medical Center, Toledo, Ohio, USA
| | - Ashutosh P Jadhav
- The Stroke Institute, Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
| | - Tudor G Jovin
- Cooper University Hospital Neurological Institute, Camden, New Jersey, USA
| | - Ahmad Khaldi
- WellStar Medical Group, Neurosurgery WellStar Health System, Marietta, Georgia, USA
| | - Rishi G Gupta
- WellStar Medical Group, Neurosurgery WellStar Health System, Marietta, Georgia, USA
| | - Andrew Johnson
- Department of Neurosurgery, Northshore University Health System, Chicago, Illinois, USA
| | - Donald Frei
- Radiology Imaging Associates, Swedish Medical Center, Englewood, Colorado, USA
| | - David Loy
- Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, Virginia, USA
| | - Adel Malek
- Department of Neurosurgery, Tufts Medical Center, Boston, Massachusetts, USA
| | - Gabor Toth
- Cerebrovascular Center, Cleveland Clinic, Cleveland, Ohio, USA
| | | | | | - Ajith Thomas
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
| | - Steven W Hetts
- Interventional Neuroradiology, University of California San Francisco, San Francisco, California, USA
| | | | - Osama O Zaidat
- Neuroscience Department, Bon Secours Mercy Health St. Vincent Medical Center, Toledo, Ohio, USA
| |
Collapse
|
37
|
Jankowitz BT, Jadhav AP, Gross B, Jovin TG, Alhajeri AA, Fraser JF, Hanel RA, Sauvageau E, Aghaebrahim A, Frei D, Bellon R, Loy D, Puri AS, Malek AM, Thomas A, Toth G, Lopes DK, Crowley RW, Arthur AS, Reavey-Cantwell J, Lin E, Siddiqui AH, Alexander MJ, Khaldi A, Colby GP, Caplan JM, Satti SR, Turk AS, Spiotta AM, Klucznik R, Hallam DK, Kung D, Froehler MT, Callison RC, Kan P, Hetts SW, Zaidat OO. Pivotal trial of the Neuroform Atlas stent for treatment of posterior circulation aneurysms: one-year outcomes. J Neurointerv Surg 2021; 14:143-148. [PMID: 33722961 PMCID: PMC8785011 DOI: 10.1136/neurintsurg-2020-017115] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2020] [Revised: 02/15/2021] [Accepted: 02/19/2021] [Indexed: 11/04/2022]
Abstract
BACKGROUND Stent-assisted coiling of wide-necked intracranial aneurysms (IAs) using the Neuroform Atlas Stent System (Atlas) has shown promising results. OBJECTIVE To present the primary efficacy and safety results of the ATLAS Investigational Device Exemption (IDE) trial in a cohort of patients with posterior circulation IAs. METHODS The ATLAS trial is a prospective, multicenter, single-arm, open-label study of unruptured, wide-necked, IAs treated with the Atlas stent and adjunctive coiling. This study reports the results of patients with posterior circulation IAs. The primary efficacy endpoint was complete aneurysm occlusion (Raymond-Roy (RR) class I) on 12-month angiography, in the absence of re-treatment or parent artery stenosis >50%. The primary safety endpoint was any major ipsilateral stroke or neurological death within 12 months. Adjudication of the primary endpoints was performed by an imaging core laboratory and a Clinical Events Committee. RESULTS The ATLAS trial enrolled and treated 116 patients at 25 medical centers with unruptured, wide-necked, posterior circulation IAs (mean age 60.2±10.5 years, 81.0% (94/116) female). Stents were placed in all patients with 100% technical success rate. A total of 95/116 (81.9%) patients had complete angiographic follow-up at 12 months, of whom 81 (85.3%) had complete aneurysm occlusion (RR class I). The primary effectiveness outcome was achieved in 76.7% (95% CI 67.0% to 86.5%) of patients. Overall, major ipsilateral stroke and secondary persistent neurological deficit occurred in 4.3% (5/116) and 1.7% (2/116) of patients, respectively. CONCLUSIONS In the ATLAS IDE posterior circulation cohort, the Neuroform Atlas Stent System with adjunctive coiling demonstrated high rates of technical and safety performance.Trial registration number https://clinicaltrials.gov/ct2/show/NCT02340585.
Collapse
Affiliation(s)
- Brian T Jankowitz
- Cooper Neurological Institute, Cooper University Hospital, Camden, New Jersey, USA
| | | | - Bradley Gross
- Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
| | - Tudor G Jovin
- Department of Neurology, Cooper University Hospital, Camden, New Jersey, USA
| | - Abdulnasser A Alhajeri
- Department of Diagnostic Radiology, Riverside Radiology and Interventional Associates Inc, Columbus, Ohio, USA
| | - Justin F Fraser
- Department of Neurological Surgery, University of Kentucky, Lexington, Kentucky, USA
| | - Ricardo A Hanel
- Baptist Health System Jacksonville, Jacksonville, Florida, USA
| | - Eric Sauvageau
- Lyerly Neurosurgery, Baptist Neurological Institute, Jacksonville, Florida, USA
| | - Amin Aghaebrahim
- Neurological Institute, Lyerley Neurosurgery, Baptist Medical Center Jacksonville, Jacksonville, Florida, USA
| | - Donald Frei
- Department of Interventional Neuroradiology, Radiology Imaging Associates, Englewood, Colorado, USA
| | - Richard Bellon
- Department of Interventional Neuroradiology, Radiology Imaging Associates, Englewood, Colorado, USA
| | - David Loy
- Department of Radiology, University of Virginia Medical Center, Charlottesville, Virginia, USA
| | - Ajit S Puri
- Department of Radiology, University of Massachusetts, Worcester, Massachusetts, USA
| | - Adel M Malek
- Department of Neurosurgery, Tufts Medical Center, Boston, Massachusetts, USA
| | - Ajith Thomas
- Department of Surgery, Division of Neurosurgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
| | - Gabor Toth
- Cerebrovascular Center, Cleveland Clinic, Cleveland, OH, USA
| | | | | | - Adam S Arthur
- Semmes-Murphey Neurologic and Spine Institute, Memphis, Tennessee, USA.,Department of Neurosurgery, University of Tennessee Health Science Center, Memphis, Tennessee, USA
| | | | - Eugene Lin
- Neuroscience Department, Mercy Health St Vincent Medical Center Department of Internal Medicine, Toledo, Ohio, USA
| | - Adnan H Siddiqui
- Department of Neurosurgery, University at Buffalo, Buffalo, New York, USA
| | - Michael J Alexander
- Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Ahmad Khaldi
- Department of Neurosurgery, Wellstar Health System, Marietta, Georgia, USA
| | - Geoffrey P Colby
- Department of Neurosurgery, University of California Los Angeles, Los Angeles, California, USA
| | - Justin M Caplan
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Sudhakar R Satti
- Department of Neurointerventional Surgery, CCHS, Newark, Delaware, USA
| | - Aquilla S Turk
- Department of Neuroradiology, Prisma Helath, Greenville, South Carolina, USA
| | - Alejandro M Spiotta
- Department of Neurosurgery, Medical University of South Carolina, Charleston, South Carolina, USA
| | - Richard Klucznik
- Division of Interventional Neuroradiology, Houston Methodist Hospital, Houston, Texas, USA
| | - Danial K Hallam
- Department of Radiology, University of Washington, Seattle, Washington, USA
| | - David Kung
- Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Michael T Froehler
- Cerebrovascular Program, Vanderbilt University, Nashville, Tennessee, USA
| | - R Charles Callison
- Department of Interventional Neurology, Lawnwood Regional Medical Center and Heart Institute, Fort Pierce, Florida, USA
| | - Peter Kan
- Department of Neurosurgery, Baylor College of Medicine, Houston, Texas, USA
| | - Steven W Hetts
- Department of Radiology, UCSF, San Francisco, California, USA
| | - Osama O Zaidat
- Department of Neuroscience, St Vincent Mercy Hospital, Toledo, Ohio, USA
| |
Collapse
|
38
|
Toth G, Kapus K, Hesszenberger D, Pohl M, Kosa G, Kiss J, Pusch G, Fejes E, Tibold A, Feher G. Internet Addiction and Burnout in A Single Hospital: Is There Any Association? Int J Environ Res Public Health 2021; 18:ijerph18020615. [PMID: 33450812 PMCID: PMC7828215 DOI: 10.3390/ijerph18020615] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 12/16/2020] [Revised: 12/27/2020] [Accepted: 01/11/2021] [Indexed: 12/19/2022]
Abstract
The extensive availability of the internet has led to the recognition of problematic internet use, the so-called Internet Addiction (IA), mostly involving adolescents. Burnout can lead to substance abuse or addictive behaviour (such as internet addiction) as a coping method. There are insufficient data about internet addiction and its possible association with burnout in adults, especially among healthcare workers. The aim of our present study was to focus on prevalence and the risk factors of internet addiction and its possible association with burnout among healthcare workers in a single hospital applying a questionnaire-based survey. In total, 49 doctors (10.1%), 198 nurses (40.9%), 123 medical assistant (25.4%), 73 other healthcare workers (15.1%), and 42 (1.7%) healthcare associated workers (cleaning, laundry, etc.) have completed our survey. In a multivariate analysis, IA was associated with age between 18 and 25 (OR: 2.6, p = 0.024), surfing on the internet >5 h daily (OR 25.583, p < 0.001), being single (OR: 4.275, p = 0.006), being childless (OR: 3.81, p = 0.011), working less than five years (OR 2.135, p = 0.048) and job type (being healthcare associated worker, OR: 2.907, p = 0.009). Illicit drug intake (OR 52.494, p < 0.001), and diabetes (OR: 4.122, p = 0.043) were also significantly associated with internet addiction. No association of burnout and IA could be found. A small but significant proportion of our healthcare workers suffered from IA, which was associated with substance abuse and diabetes in multivariate analysis. Our study also draws attention to the risk factors of IA such as younger age, family status, working type and working hours internet use. The possible association of burnout and IA merits further investigation.
Collapse
Affiliation(s)
- Gabor Toth
- Centre for Occupational Medicine, Medical School, University of Pécs, 7627 Pécs, Hungary; (G.T.); (K.K.); (M.P.); (G.K.); (J.K.); (E.F.); (A.T.)
- Szent Rókus Hospital, 1085 Baja, Hungary
| | - Krisztian Kapus
- Centre for Occupational Medicine, Medical School, University of Pécs, 7627 Pécs, Hungary; (G.T.); (K.K.); (M.P.); (G.K.); (J.K.); (E.F.); (A.T.)
| | - David Hesszenberger
- Department of Laboratory Medicine, Medical School, University of Pecs, 7627 Pécs, Hungary;
| | - Marietta Pohl
- Centre for Occupational Medicine, Medical School, University of Pécs, 7627 Pécs, Hungary; (G.T.); (K.K.); (M.P.); (G.K.); (J.K.); (E.F.); (A.T.)
| | - Gabor Kosa
- Centre for Occupational Medicine, Medical School, University of Pécs, 7627 Pécs, Hungary; (G.T.); (K.K.); (M.P.); (G.K.); (J.K.); (E.F.); (A.T.)
| | - Julianna Kiss
- Centre for Occupational Medicine, Medical School, University of Pécs, 7627 Pécs, Hungary; (G.T.); (K.K.); (M.P.); (G.K.); (J.K.); (E.F.); (A.T.)
| | - Gabriella Pusch
- Department of Neurology, Medical School, University of Pecs, 7627 Pécs, Hungary;
| | - Eva Fejes
- Centre for Occupational Medicine, Medical School, University of Pécs, 7627 Pécs, Hungary; (G.T.); (K.K.); (M.P.); (G.K.); (J.K.); (E.F.); (A.T.)
- Hospital of Komlo, 7300 Komlo, Hungary
| | - Antal Tibold
- Centre for Occupational Medicine, Medical School, University of Pécs, 7627 Pécs, Hungary; (G.T.); (K.K.); (M.P.); (G.K.); (J.K.); (E.F.); (A.T.)
| | - Gergely Feher
- Centre for Occupational Medicine, Medical School, University of Pécs, 7627 Pécs, Hungary; (G.T.); (K.K.); (M.P.); (G.K.); (J.K.); (E.F.); (A.T.)
- Neurology Outpatient Clinic, EÜ-MED KFT, 7300 Komlo, Hungary
- Correspondence: ; Tel.: +36-72518-523; Fax: 36-72518-521
| |
Collapse
|
39
|
Toth G, Wijns W, Fournier S, Toth B, Johnson N, Barbato E. Revascularization decisions in patients with stable angina and intermediate lesions: results of the second International Survey on Interventional Strategy (ISIS-2). Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
ISIS-1 survey (conducted in 2012–2013) demonstrated a significant disconnect between guideline recommendations on invasive functional and imaging assessment of coronary stenosis severity and effective intention to adoption in patients with chronic coronary syndromes (CCS). Ever since, more evidences and new indexes/tools have become available, supposedly resulting into a simplified adoption. Therefore, six years later the second survey was repeated (ISIS-2) with the aim to evaluate a possible evolution in the intended adoption of invasive diagnostic tools.
Methods
ISIS-2 was conducted via a web-based platform from June to December 2019. Here, five complete angiograms were provided, presenting only focal intermediate stenoses. FFR and quantitative coronary angiography (QCA) values were known and kept concealed to the participants. Estimation of stenosis significance was asked for each lesion. In case of uncertainty, the most appropriate adjunctive invasive diagnostic method among QCA, intravascular ultrasound, optical coherence tomography, or invasive functional test (i.e. with FFR or a non-hyperemic index) was to be selected. Primary endpoint of the study was the rate of requested adjunctive functional or imaging assessment, as indicated by guideline recommendations. Secondary endpoint was the rate and accuracy of purely angiography-based decisions.
Results
A total of 411 participants performed 3749 lesion evaluations in ISIS-2: 2237 (60%) decisions were taken solely on angiogram and expressed no need for further evaluation with adjunctive tools. This rate of angiographic reliance was significantly reduced in ISIS-2 as compared with ISIS-1 (3139 [71%]; p<0.001). Here the decision (significant or non-significant) was discordant with the known functional significance in 870 (39%) cases, markedly less as in ISIS-1 (1459, 46%; p<0.001). In ISIS-2, participants expressed the need for either invasive functional assessment or intravascular imaging in 1110 (29%) and 379 (11%) cases, respectively. These rates were significantly higher as compared with ISIS-1 (928 [21%]; p<0.001 and 354 [8%]; p<0.001, respectively).
Conclusions
ISIS-2 survey suggests an evolving pattern over 6 years in the intention to integrate coronary angiography with invasive coronary physiology and imaging testing in patients with CCS.
Funding Acknowledgement
Type of funding source: Private company. Main funding source(s): Unrestricted grant from Abbott Medical
Collapse
Affiliation(s)
- G Toth
- Medical University of Graz, Graz, Austria
| | - W Wijns
- Galway University Hospital, Galway, Ireland
| | - S Fournier
- University of Lausanne, Lausanne, Switzerland
| | - B Toth
- Freelancer, Sopron, Hungary
| | - N Johnson
- University of Texas Health Science Center, Houston, United States of America
| | - E Barbato
- Federico II University of Naples, Naples, Italy
| |
Collapse
|
40
|
Toth G, Sasi V, Franco D, Di Serafino L, Prassl A, Ng J, Szanto G, Plank G, Ang HY, Wijns W, Barbato E. TCT CONNECT-153 Double-Kissing Culotte Technique for Coronary Bifurcation Stenting: Technical Evaluation and Comparison With Conventional Double-Stenting Techniques. J Am Coll Cardiol 2020. [DOI: 10.1016/j.jacc.2020.09.163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
41
|
Affiliation(s)
- Gabor Toth
- Cerebrovascular Center, Cleveland Clinic Foundation, Cleveland, Ohio, USA
| | - Alejandro M Spiotta
- Department of Neurosurgery, Medical University of South Carolina, Charleston, South Carolina, USA
| | - Joshua A Hirsch
- NeuroEndovascular Program, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - David Fiorella
- Department of Neurosurgery, Stony Brook University, Stony Brook, New York, USA
| |
Collapse
|
42
|
Alexander MJ, Zauner A, Gupta R, Alshekhlee A, Fraser JF, Toth G, Given C, Mackenzie L, Kott B, Hassan AE, Shownkeen H, Baxter BW, Callison RC, Yu W. The WOVEN trial: Wingspan One-year Vascular Events and Neurologic Outcomes. J Neurointerv Surg 2020; 13:307-310. [PMID: 32561658 DOI: 10.1136/neurintsurg-2020-016208] [Citation(s) in RCA: 64] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2020] [Revised: 05/15/2020] [Accepted: 05/19/2020] [Indexed: 11/03/2022]
Abstract
BACKGROUND Prior studies evaluating the Wingspan stent for treatment of symptomatic intracranial atherosclerotic disease have included patients with a spectrum of both on-label and off-label indications for the stent. The WEAVE trial assessed 152 patients stented with the Wingspan stent strictly by its current on-label indication and found a 2.6% periprocedural stroke and death rate. OBJECTIVE This WOVEN study assesses the 1-year follow-up from this cohort. METHODS Twelve of the original 24 sites enrolling patients in the WEAVE trial performed follow-up chart review and imaging analysis up to 1 year after stenting. Assessment of delayed stroke and death was made in 129 patients, as well as vascular imaging follow-up to assess for in-stent re-stenosis. RESULTS In the 1-year follow-up period, seven patients had a stroke (six minor, one major). Subsequent to the periprocedural period, no deaths were recorded in the cohort. Including the four patients who had periprocedural events in the WEAVE study, there were 11 strokes or deaths of the 129 patients (8.5%) at the 1-year follow-up. CONCLUSIONS The WOVEN study provides the 1-year follow-up on a cohort of 129 patients who were stented according to the current on-label use. It provides a more homogeneous patient group for analysis than prior studies, and demonstrates a relatively low 8.5% 1-year stroke and death rate in stented patients.
Collapse
Affiliation(s)
- Michael J Alexander
- Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Alois Zauner
- Department of Neurosurgery, Stroke and Neurovascular Center of Central California, Santa Barbara, California, USA
| | - Rishi Gupta
- Neuroscience Department, WellStar Medical Group, Marietta, Georgia, USA
| | - Amer Alshekhlee
- Department of Neurology, SSM Health, St. Louis, Missouri, USA
| | - Justin F Fraser
- Department of Neurological Surgery, University of Kentucky, Lexington, Kentucky, USA
| | - Gabor Toth
- Cerebrovascular Center, CCF, Cleveland Heights, Ohio, USA
| | - Curtis Given
- Baptist Health Lexington, Lexington, Kentucky, USA
| | - Larami Mackenzie
- Department of Neurosurgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
| | - Brian Kott
- Department of Radiology, MultiCare Health System, Tacoma, Washington, USA
| | - Ameer E Hassan
- Department of Neurology, University of Minnesota, Minneapolis, Minnesota, USA
| | | | - Blaise W Baxter
- Department of Radiology, University of Tennessee, Knoxville, Tennessee, USA
| | - R Charles Callison
- Department of Neurology, Lawnwood Regional Medical Center and Heart Institute, Fort Pierce, Florida, USA
| | - Wengui Yu
- Department of Neurology, University of California Irvine, Irvine, California, USA
| |
Collapse
|
43
|
Zaidat OO, Hanel RA, Sauvageau EA, Aghaebrahim A, Lin E, Jadhav AP, Jovin TG, Khaldi A, Gupta RG, Johnson A, Frei D, Loy D, Malek A, Toth G, Siddiqui A, Reavey-Cantwell J, Thomas A, Hetts SW, Jankowitz BT. Pivotal Trial of the Neuroform Atlas Stent for Treatment of Anterior Circulation Aneurysms: One-Year Outcomes. Stroke 2020; 51:2087-2094. [PMID: 32568654 PMCID: PMC7306258 DOI: 10.1161/strokeaha.119.028418] [Citation(s) in RCA: 43] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND AND PURPOSE Stent-assisted coil embolization using the new generation Neuroform Atlas Stent System has shown promising safety and efficacy. The primary study results of the anterior circulation aneurysm cohort of the treatment of wide-neck, saccular, intracranial, aneurysms with the Neuroform Atlas Stent System (ATLAS trial [Safety and Effectiveness of the Treatment of Wide Neck, Saccular Intracranial Aneurysms With the Neuroform Atlas Stent System]) are presented. METHODS ATLAS IDE trial (Investigational Device Exemption) is a prospective, multicenter, single-arm, open-label study of wide-neck (neck ≥4 mm or dome-to-neck ratio <2) intracranial aneurysms in the anterior circulation treated with the Neuroform Atlas Stent and approved coils. The primary efficacy end point was complete aneurysm occlusion (Raymond-Roy class 1) on 12-month angiography, in the absence of retreatment or parent artery stenosis (>50%) at the target location. The primary safety end point was any major stroke or ipsilateral stroke or neurological death within 12 months. Adjudication of the primary end points was performed by an independent Imaging Core Laboratory and the Clinical Events Committee. RESULTS A total of 182 patients with wide-neck anterior circulation aneurysms at 25 US centers were enrolled. The mean age was 60.3±11.4 years, 73.1% (133/182) women, and 80.8% (147/182) white. Mean aneurysm size was 6.1±2.2 mm, mean neck width was 4.1±1.2 mm, and mean dome-to-neck ratio was 1.2±0.3. The most frequent aneurysm locations were the anterior communicating artery (64/182, 35.2%), internal carotid artery ophthalmic artery segment (29/182, 15.9%), and middle cerebral artery bifurcation (27/182, 14.8%). Stents were placed in the anticipated anatomic location in all patients. The study met both primary safety and efficacy end points. The composite primary efficacy end point of complete aneurysm occlusion (Raymond-Roy 1) without parent artery stenosis or aneurysm retreatment was achieved in 84.7% (95% CI, 78.6%-90.9%) of patients. Overall, 4.4% (8/182, 95% CI, 1.9%-8.5%) of patients experienced a primary safety end point of major ipsilateral stroke or neurological death. CONCLUSIONS In the ATLAS IDE anterior circulation aneurysm cohort premarket approval study, the Neuroform Atlas stent with adjunctive coiling met the primary end points and demonstrated high rates of long-term complete aneurysm occlusion at 12 months, with 100% technical success and <5% morbidity. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02340585.
Collapse
Affiliation(s)
- Osama O Zaidat
- Neuroscience Department, Bon Secours Mercy Health St. Vincent Medical Center, Toledo, OH (O.O.Z., E.L.)
| | - Ricardo A Hanel
- Lyerly Neurosurgery, Jacksonville, FL (R.A.H., E.A.S., A.A.)
| | | | | | - Eugene Lin
- Neuroscience Department, Bon Secours Mercy Health St. Vincent Medical Center, Toledo, OH (O.O.Z., E.L.)
| | - Ashutosh P Jadhav
- The Stroke Institute, Department of Neurology, University of Pittsburgh Medical Center, PA (A.P.J.)
| | - Tudor G Jovin
- Cooper University Hospital Neurological Institute, Camden, NJ (T.G.J.)
| | - Ahmad Khaldi
- WellStar Medical Group, Neurosurgery WellStar Health System, Marietta, GA (A.K., R.G.G.)
| | - Rishi G Gupta
- WellStar Medical Group, Neurosurgery WellStar Health System, Marietta, GA (A.K., R.G.G.)
| | - Andrew Johnson
- Swedish Covenant Hospital Neurosurgery, Chicago, IL (A.J.)
| | - Donald Frei
- Radiology Imaging Associates, Swedish Medical Center, Englewood, CO (D.F.)
| | - David Loy
- Department of Radiology and Medical Imaging, University of Virginia, Charlottesville (D.L.)
| | - Adel Malek
- Department of Neurosurgery, Tufts Medical Center, Boston, MA (A.M.)
| | - Gabor Toth
- Cerebrovascular Center, Cleveland Clinic, OH (G.T.)
| | | | | | - Ajith Thomas
- Beth Israel Deaconess Medical Center, Boston, MA (A.T.)
| | - Steven W Hetts
- Interventional Neuroradiology, University of California San Francisco, San Francisco (S.W.H.)
| | | | | |
Collapse
|
44
|
Belafi-Bako K, Toth G, Nemestothy N. Application of polymer membranes in downstream processes. Physical Sciences Reviews 2020. [DOI: 10.1515/psr-2018-0070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
AbstractThe purpose of downstream processing in a fermentation technology is the isolation, purification and concentration of the final product. Membrane processes are generally used in these steps. In this paper, the application possibilities of polymer membranes in pressure-driven membrane techniques (microfiltration, ultrafiltration, nanofiltration), pervaporation, dialysis and electrodialysis are presented.
Collapse
Affiliation(s)
- Katalin Belafi-Bako
- Research Institute on Biochemical Engineering, Membrane Technology and Energetics, University of Pannonia, Egyetem u. 10., 8200Veszprem, Hungary
| | - Gabor Toth
- Research Institute on Biochemical Engineering, Membrane Technology and Energetics, University of Pannonia, Egyetem u. 10., 8200Veszprem, Hungary
| | - Nandor Nemestothy
- Research Institute on Biochemical Engineering, Membrane Technology and Energetics, University of Pannonia, Egyetem u. 10., 8200Veszprem, Hungary
| |
Collapse
|
45
|
Combi M, Shou Y, Fougere N, Tenishev V, Altwegg K, Rubin M, Bockelée-Morvan D, Capaccioni F, Cheng YC, Fink U, Gombosi T, Hansen KC, Huang Z, Marshall D, Toth G. The Surface Distributions of the Production of the Major Volatile Species, H 2O, CO 2, CO and O 2, from the Nucleus of Comet 67P/Churyumov-Gerasimenko throughout the Rosetta Mission as Measured by the ROSINA Double Focusing Mass Spectrometer. Icarus 2020; 335:113421. [PMID: 31631900 PMCID: PMC6800715 DOI: 10.1016/j.icarus.2019.113421] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
The Rosetta Orbiter Spectrometer for Ion and Neutral Analysis (ROSINA) suite of instruments operated throughout the over two years of the Rosetta mission operations in the vicinity of comet 67P/Churyumov-Gerasimenko. It measured gas densities and composition throughout the comet's atmosphere, or coma. Here we present two-years' worth of measurements of the relative densities of the four major volatile species in the coma of the comet, H2O, CO2, CO and O2, by one of the ROSINA sub-systems called the Double Focusing Mass Spectrometer (DFMS). The absolute total gas densities were provided by the Comet Pressure Sensor (COPS), another ROSINA sub-system. DFMS is a very high mass resolution and high sensitivity mass spectrometer able to resolve at a tiny fraction of an atomic mass unit. We have analyzed the combined DFMS and COPS measurements using an inversion scheme based on spherical harmonics that solves for the distribution of potential surface activity of each species as the comet rotates, changing solar illumination, over short time intervals and as the comet changes distance from the sun and orientation of its spin axis over long time intervals. We also use the surface boundary conditions derived from the inversion scheme to simulate the whole coma with our fully kinetic Direct Simulation Monte Carlo model and calculate the production rates of the four major species throughout the mission. We compare the derived production rates with revised remote sensing observations by the Visible and Infrared Thermal Imaging Spectrometer (VIRTIS) as well as with published observations from the Microwave Instrument for the Rosetta Orbiter (MIRO). Finally we use the variation of the surface production of the major species to calculate the total mass loss over the mission and, for different estimates of the dust/gas ratio, calculate the variation of surface loss all over the nucleus.
Collapse
Affiliation(s)
- Michael Combi
- Department of Climate and Space Sciences and Engineering, University of Michigan, Ann Arbor, Michigan, USA
| | - Yinsi Shou
- Department of Climate and Space Sciences and Engineering, University of Michigan, Ann Arbor, Michigan, USA
| | - Nicolas Fougere
- Department of Climate and Space Sciences and Engineering, University of Michigan, Ann Arbor, Michigan, USA
| | - Valeriy Tenishev
- Department of Climate and Space Sciences and Engineering, University of Michigan, Ann Arbor, Michigan, USA
| | - Kathrin Altwegg
- Physikalisches Institut, University of Bern, Bern, Switzerland
| | - Martin Rubin
- Physikalisches Institut, University of Bern, Bern, Switzerland
| | - Dominique Bockelée-Morvan
- LESIA, Observatoire de Paris, PSL Research University, CNRS, Sorbonne Universites, UPMC Univ. Paris 06, Univ. Paris-Diderot, Sorbonne Paris Cité, 5 place Jules Janssen, F-92195 Meudon, France
| | - Fabrizio Capaccioni
- 4INAF-IAPS, Istituto di Astrofisica e Planetologia Spaziali, via del fosso del Cavaliere 100, I-00133 Rome, Italy
| | - Yu-Chi Cheng
- LESIA, Observatoire de Paris, PSL Research University, CNRS, Sorbonne Universites, UPMC Univ. Paris 06, Univ. Paris-Diderot, Sorbonne Paris Cité, 5 place Jules Janssen, F-92195 Meudon, France
| | - Uwe Fink
- Lunar and Planetary Laboratory, University of Arizona, Tucson, Arizona, USA
| | - Tamas Gombosi
- Department of Climate and Space Sciences and Engineering, University of Michigan, Ann Arbor, Michigan, USA
| | - Kenneth C Hansen
- Department of Climate and Space Sciences and Engineering, University of Michigan, Ann Arbor, Michigan, USA
| | - Zhenguang Huang
- Department of Climate and Space Sciences and Engineering, University of Michigan, Ann Arbor, Michigan, USA
| | - David Marshall
- Max-Planck-Institut für Sonnensystemforschung, Justus-von-Liebig-Weg 3, 37077 Göttingen, Germany
| | - Gabor Toth
- Department of Climate and Space Sciences and Engineering, University of Michigan, Ann Arbor, Michigan, USA
| |
Collapse
|
46
|
Saito Y, Wijns W, Baumbach A, Xu B, Kelbæk H, van Royen N, Zheng M, Knaapen P, Slagboom T, Johnson T, Vlachojannis G, Holmvang L, Janssens L, Ochala A, Brugaletta S, Anderson R, Rittger H, Berti S, Barbato E, Toth G, Maillard L, Valina C, Buszman P, Thiele H, Lansky A. TCT-287 Impact of Eligibility Criteria on Clinical Outcomes of Firehawk and XIENCE Coronary Drug-Eluting Stent in an All-Comers Randomized Trial. J Am Coll Cardiol 2019. [DOI: 10.1016/j.jacc.2019.08.361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
47
|
Toth G, Ortega-Gutierrez S, Tsai JP, Cerejo R, Al Kasab S, Uchino K, Hussain MS, Bain M, Bullen J, Samaniego EA. The Safety and Feasibility of Mechanical Thrombectomy for Mild Acute Ischemic Stroke With Large Vessel Occlusion. Neurosurgery 2019; 86:802-807. [DOI: 10.1093/neuros/nyz354] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2019] [Accepted: 06/18/2019] [Indexed: 11/12/2022] Open
Abstract
Abstract
BACKGROUND
Prospective evidence to support mechanical thrombectomy (MT) for mild ischemic stroke with large vessel occlusion (LVO) is lacking. There is uncertainty about using an invasive procedure in patients with mild symptoms.
OBJECTIVE
To evaluate the safety and feasibility of MT in patients with mild symptoms and LVO.
METHODS
Our single-arm prospective pilot study recruited patients with LVO and initial National Institute of Health Stroke Scale (NIHSS) <6, who underwent standard MT. Primary safety endpoints were symptomatic intracerebral hemorrhage (sICH), and/or worsening NIHSS by ≥4 points. Secondary endpoints included angiographic recanalization, NIHSS change, final infarct volume, and modified Rankin score (mRS).
RESULTS
We enrolled 20 patients (mean age 65.6 ± 12.3 yr; 45% females). Thrombolysis in Cerebral Ischemia 2B/3 thrombectomy was achieved in 95%. No patients suffered sICH. One patient (5%) had neurologic worsening within 24 h because of underlying intracranial stenosis. No other complications or safety concerns were identified. Median NIHSS was significantly better at discharge (0.5, P = .007) and at last follow-up (0, P < .001) than before treatment (3). Mean post vs preintervention infarct volumes were small without significant difference (1.2 ml, P = .434). Most patients (85%) were discharged directly home. Excellent clinical outcome (mRS 0-1) at last follow-up was seen in 95% of patients.
CONCLUSION
This is one of the first specifically designed prospective studies showing that MT is safe and feasible in patients with low NIHSS and LVO. Chronic underlying vasculopathy may be a challenging dilemma. We observed excellent clinical and radiographic outcomes, but randomized controlled trials are needed to demonstrate the efficacy of MT in this unique cohort.
Collapse
Affiliation(s)
- Gabor Toth
- Cerebrovascular Center, Cleveland Clinic, Cleveland, Ohio
| | - Santiago Ortega-Gutierrez
- Department of Neurology, University of Iowa Hospitals and Clinics, Iowa City, Iowa
- Department of Neurosurgery, University of Iowa Hospitals and Clinics, Iowa City, Iowa
- Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City, Iowa
| | - Jenny P Tsai
- Cerebrovascular Center, Cleveland Clinic, Cleveland, Ohio
| | - Russell Cerejo
- Cerebrovascular Center, Allegheny Health Network, Pittsburgh, Pennsylvania
| | - Sami Al Kasab
- Department of Neurology, University of Iowa Hospitals and Clinics, Iowa City, Iowa
- Department of Neurosurgery, University of Iowa Hospitals and Clinics, Iowa City, Iowa
- Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City, Iowa
| | - Ken Uchino
- Cerebrovascular Center, Cleveland Clinic, Cleveland, Ohio
| | | | - Mark Bain
- Cerebrovascular Center, Cleveland Clinic, Cleveland, Ohio
| | - Jennifer Bullen
- Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio
| | - Edgar A Samaniego
- Department of Neurology, University of Iowa Hospitals and Clinics, Iowa City, Iowa
- Department of Neurosurgery, University of Iowa Hospitals and Clinics, Iowa City, Iowa
- Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City, Iowa
| |
Collapse
|
48
|
Fabian E, Reglodi D, Horvath G, Opper B, Toth G, Fazakas C, Vegh AG, Wilhelm I, Krizbai IA. Pituitary adenylate cyclase activating polypeptide acts against neovascularization in retinal pigment epithelial cells. Ann N Y Acad Sci 2019; 1455:160-172. [PMID: 31317557 DOI: 10.1111/nyas.14189] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2019] [Revised: 05/30/2019] [Accepted: 06/14/2019] [Indexed: 12/31/2022]
Abstract
The purpose of this study was to determine whether pituitary adenylate cyclase activating polypeptide (PACAP) could influence the neovascularization processes in hyperosmotic and oxidative stress in retinal pigment epithelial cells. Hyperosmotic conditions and oxidative stress were induced by 200 mM sucrose and 250 µM hydrogen peroxide (H2 O2 ), respectively. Morphology and elasticity of adult retinal pigment epithelial (ARPE-19) cells were measured by atomic force microscopy, while the investigation of junctional molecules, such as occludin and ZO-1, was carried out using immunofluorescence. For cell viability measurement, the MTT test was used. The effect of PACAP on the key angiogenic factors, such as vascular endothelial growth factor, angiogenin, and endothelin-1, was measured by an angiogenesis array and flow cytometry. Hyperosmotic stress-induced reorganization of the cytoskeleton and impairment of the junctions decreased cell viability and upregulated several angiogenic factors. In oxidative stress, we found that opening of the junctions decreased viability and upregulated the expression of angiogenic factors. PACAP was shown to be protective in both conditions. Retinal pigment epithelium cells play an important role in several diseases, such as diabetic retinopathy and macular edema. Therefore, protecting retinal pigment epithelial (RPE) cells with PACAP could be a novel and potential treatment in these diseases.
Collapse
Affiliation(s)
- Eszter Fabian
- Department of Anatomy, University of Pécs, Medical School, MTA-PTE PACAP Research Group, Pécs, Hungary
| | - Dora Reglodi
- Department of Anatomy, University of Pécs, Medical School, MTA-PTE PACAP Research Group, Pécs, Hungary
| | - Gabriella Horvath
- Department of Anatomy, University of Pécs, Medical School, MTA-PTE PACAP Research Group, Pécs, Hungary
| | - Balazs Opper
- Department of Anatomy, University of Pécs, Medical School, MTA-PTE PACAP Research Group, Pécs, Hungary
| | - Gabor Toth
- Department of Medical Chemistry, University of Szeged, Szeged, Hungary
| | - Csilla Fazakas
- Institute of Biophysics, Biological Research Centre, Hungarian Academy of Sciences, Szeged, Hungary
| | - Attila G Vegh
- Institute of Biophysics, Biological Research Centre, Hungarian Academy of Sciences, Szeged, Hungary
| | - Imola Wilhelm
- Institute of Biophysics, Biological Research Centre, Hungarian Academy of Sciences, Szeged, Hungary.,Institute of Life Sciences, Vasile Goldiş Western University of Arad, Arad, Romania
| | - Istvan A Krizbai
- Institute of Biophysics, Biological Research Centre, Hungarian Academy of Sciences, Szeged, Hungary.,Institute of Life Sciences, Vasile Goldiş Western University of Arad, Arad, Romania
| |
Collapse
|
49
|
Hanel RA, Kallmes DF, Lopes DK, Nelson PK, Siddiqui A, Jabbour P, Pereira VM, Szikora István I, Zaidat OO, Bettegowda C, Colby GP, Mokin M, Schirmer C, Hellinger FR, Given Ii C, Krings T, Taussky P, Toth G, Fraser JF, Chen M, Priest R, Kan P, Fiorella D, Frei D, Aagaard-Kienitz B, Diaz O, Malek AM, Cawley CM, Puri AS. Prospective study on embolization of intracranial aneurysms with the pipeline device: the PREMIER study 1 year results. J Neurointerv Surg 2019; 12:62-66. [PMID: 31308197 PMCID: PMC6996098 DOI: 10.1136/neurintsurg-2019-015091] [Citation(s) in RCA: 161] [Impact Index Per Article: 32.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2019] [Revised: 06/19/2019] [Accepted: 06/21/2019] [Indexed: 11/25/2022]
Abstract
Background Preliminary clinical studies on the safety and efficacy of the pipeline embolization device (PED) for the treatment of small/medium aneurysms have demonstrated high occlusion rates with low complications. Objective To evaluate the safety and effectiveness of the PED for treatment of wide necked small and medium intracranial aneurysms. Methods PREMIER is a prospective, multicenter, single arm trial. Patients were treated with the PED for unruptured wide necked aneurysms, measuring ≤12 mm along the internal carotid artery or vertebral artery, between July 2014 and November 2015. At 1 year post-procedure, the primary effectiveness endpoint was complete occlusion (Raymond grade 1) without major parent vessel stenosis (≤50%) or retreatment, and the primary safety endpoint was major stroke in the territory supplied by the treated artery or neurologic death. Results A total of 141 patients were treated with PEDs (mean age 54.6±11.3 years, 87.9% (124/141) women). Mean aneurysm size was 5.0±1.92 mm, and 84.4% (119/141) measured <7 mm. PED placement was successful in 99.3% (140/141) of patients. Mean number of PEDs implanted per patient was 1.1±0.26; a single PED was used in 92.9% (131/141) of patients. At 1 year, 97.9% (138/141) of patients underwent follow-up angiography with 76.8% (106/138) of patients having met the study’s primary effectiveness endpoint. The combined major morbidity and mortality rate was 2.1% (3/140). Conclusions Treatment of wide necked small/medium aneurysms with the PED results in high rates of complete occlusion without significant parent vessel stenosis and low rates of permanent neurologic complications. Trial registration NCT02186561.
Collapse
Affiliation(s)
- Ricardo A Hanel
- Baptist Neurological Institute, Lyerly Neurosurgery, Jacksonville, Florida, USA
| | - David F Kallmes
- Departments of Neurosurgery and Radiology, Mayo Clinic, Rochester, Minnesota, USA
| | | | - Peter Kim Nelson
- Interventional Radiology, New York University Langone Medical Center, New York, New York, USA
| | - Adnan Siddiqui
- Departments of Neurosurgery and Radiology, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA
| | - Pascal Jabbour
- Department of Neurosurgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA
| | - Vitor M Pereira
- Departments of Medical Imaging and Surgery, Division of Neuroradiology and Neurosurgery, Toronto Western Hospital, Toronto, Ontario, Canada
| | - Istvan Szikora István
- Department of Neuroradiology, National Institute of Neurosciences, Budapest, Hungary
| | - Osama O Zaidat
- Neuroscience Institute, St Vincent Mercy Hospital, Toledo, Ohio, USA
| | - Chetan Bettegowda
- Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Geoffrey P Colby
- Department of Neurosurgery, University of California Los Angeles, Los Angeles, California, USA
| | - Maxim Mokin
- Department of Neurosurgery, University of South Florida, Tampa, Florida, USA
| | - Clemens Schirmer
- Department of Neurological Surgery, Geisinger Clinic, Danville, Pennsylvania, USA
| | - Frank R Hellinger
- Department of Radiology, Florida Hospital Neuroscience Institute, Winter Park, Florida, USA
| | - Curtis Given Ii
- Department of Radiology, Baptist Health Lexington, Lexington, Kentucky, USA
| | - Timo Krings
- Department of Medical Imaging, Toronto Western Hospital, Toronto, Ontario, Canada
| | - Philipp Taussky
- Department of Neurosurgery, University of Utah, Salt Lake City, Utah, USA
| | - Gabor Toth
- Cerebrovascular Center, Cleveland Clinic, Cleveland, Ohio, USA
| | - Justin F Fraser
- Department of Neurological Surgery, University of Kentucky, Lexington, Kentucky, USA
| | - Michael Chen
- Department of Neurological Surgery, Rush University Medical Center, Chicago, Illinois, USA
| | - Ryan Priest
- Charles T Dotter Department of Interventional Radiology, Dotter Interventional Institute, Oregon Health and Science University, Portland, Oregon, USA
| | - Peter Kan
- Department of Neurosurgery, Baylor College of Medicine, Houston, Texas, USA
| | - David Fiorella
- Department of Neurosurgery, Cerebrovascular Center, Stony Brook University, Stony Brook, New York, USA
| | - Don Frei
- Department of Neuroradiology, Swedish Medical Center, Denver, Colorado, USA
| | - Beverly Aagaard-Kienitz
- Department of Neurological Surgery, University of Wisconsin Madison School of Medicine and Public Health, Madison, Wisconsin, USA
| | - Orlando Diaz
- Division of Interventional Neuroradiology, Houston Methodist Research Institute, Houston, Texas, USA
| | - Adel M Malek
- Department of Neurosurgery, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
| | - C Michael Cawley
- Departments of Neurointerventional Radiology and Neurosurgery, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Ajit S Puri
- New England Center for Stroke Research, Department of Radiology, University of Massachusetts Medical School, Worcester, Massachusetts, USA
| |
Collapse
|
50
|
Barbato E, Mauri J, Byrne RA, Roffi M, Fitzsimons D, Toth G, Capodanno D, Mehilli J, Petronio AS, Chieffo A, Vardas P, Naber CK, Dudek D, Haude M, Baumbach A. Patient focus in interventional cardiology: proceedings of the 2018 summit of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) - Nice, France, 20-21 June 2018. EUROINTERVENTION 2019; 14:1720-1723. [PMID: 31023642 DOI: 10.4244/eijv14i17a297] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Affiliation(s)
- Emanuele Barbato
- Division of Cardiology, Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|